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Background: The Retinal Degenerative Diseases (RDD) Research Group in the 
Division of Human Genetics at UCT has for the past 25 years been intensively 
investigating a range of RDD phenotypes.  Two points of particular note have emerged 
regarding  Macular Degenerations (MD): (i) that more than 58% of juvenile MD, notably 
Stargardt Disease (STGD), in Caucasian populations may have the underlying 
causative genetic defect identified, while only 11% of the similar phenotype in 
indigenous African populations is resolved, and (ii) that the ‘elderly’ form of MD, i.e. age-
related macular degeneration (AMD) has a remarkably lower incidence in the 
indigenous African population when compared to any other population group, and most 
notably the Caucasian (or European-derived) population/s.   This study investigates the 
genetic factors underlying macular degeneration (MD) in our study cohort comprising 
various South African ethnolinguistic groups with particular focus on disease in juvenile 
and elderly indigenous Africans.  
 
Materials and Methods: For the STGD part of the study, sequencing of the entire 
ABCA4 coding and splice region (comprising 50 amplicons) was performed in three 
African STGD patients who were representative of three common haplotypes identified 
within the larger cohort of 36 patients. Pathogenicity predictive software, PON-P and 
Human Splice Finder (HSF), were used for in silico data analysis.  
For the AMD subset:  Available local indigenous southern African population-based 
genome-wide Single Nucleotide Polymorphism (SNP) chip (Affymetrix SNP6) data was 
used to identify SNPs within known AMD candidate genes in which allele frequencies 
were significantly different (i.e. 10 fold) between Caucasians and indigenous southern 
Africans.  Nine SNPs occurring at higher frequencies within Africans compared to 
Caucasian controls were genotyped by SNaPshot PCR within a multi-ethnic AMD SA 
cohort. Minor allele frequencies (MAF) were compared using SHEsis. 
 
Results: Sequencing of ABCA4 in three African STGD patients produced 39 unique 
variants, out of which only one, (V643M), was deemed pathogenic. HSF predicted 22 of 
xv 
 
these non-exonic variants to be ‘possibly pathogenic’, confounding analysis. No variants 
segregated with the common haplotypes.  
Regarding the AMD cohort, eight SNPs in candidate AMD genes showed a decreased 
MAF in African AMD cases compared to controls, two  of which (rs9621622 in TIMP3 
and rs17110714 in ABCA4), were statistically significant ( p values of 9.95 x 10-4 and 
1.04 x 10-2, respectively).  
 
Discussion and Conclusion: Although a number of variants were identified in the 
coding region of three haplotype-representative STGD subjects, only one variant proved 
pathogenic but did not co-segregate with the haplotype in the rest of the samples. It is 
possible that variants in regulatory regions not captured by the exonic screening might 
be involved, or that another gene may be implicated in the ‘STGD-like’ phenotype in the 
indigenous African subjects. In the second part of the study, the investigation of the 
African AMD cohort suggested that SNPs in TIMP3 and ABCA4 are associated with a 
decreased susceptibility, and may therefore plausibly be protective for AMD in 
indigenous Africans.  Overall, however, this should be considered only a pilot study of 
macular degeneration in the indigenous African population, providing leads to larger 




Chapter 1: Introduction 
 
1.1 Anatomy of the Human Eye 
 
The human eye, encased within the orbital cavity formed by the frontal, sphenoid, 
maxillary and zygomatic bones, comprises three distinct anatomical layers (Moore. 
2013) (Figure 1.1). Structures within these three layers are discussed below. 
 
 
Figure 1.1: An illustration of a cross-sectional view of the human eye featuring 
important structures and the layers.  
Reproduced from the website Bionicvision Australia: 
http://bionicvision.org.au/eye/healthy_vision  
   
  1.1.1 The fibrous tunic 
 
The outer layer, also termed the fibrous tunic, is formed posteriorly by the opaque sclera 
and anteriorly by the translucent cornea. The sclera serves as the collagenous, 
protective boundary providing insertion points for the extrinsic ocular muscles, enabling 
rotation of the eye. It adjoins anteriorly to the avascular dome-shaped cornea which acts 






  1.1.2 The uvea   
 
The middle layer, also termed the vascular tunic or uvea, includes the choroid, ciliary 
body and iris. 
  
    1.1.2.1 Iris and ciliary body 
 
Anteriorly, the iris is a diaphragm-like sphincter extending from the ciliary body that 
controls the aperture size of the pupil in order to regulate the amount of incoming light. 
The posterior stratum of the iris, the iris pigment epithelium (IPE), is coated in a high 
concentration of the pigment melanin and determines a person’s eye colour. Darker 
coloured irises are due to additional melanin located in a fibro-vascular layer in the iris 
called the stroma.  
 
Surrounding the iris is a muscular circular structure, the ciliary body that enables 
accommodation by shaping the lens anchored to it via suspensory ligaments. 
Epithelium lining the ciliary body produces aqueous humour which fills the anterior and 
posterior chambers, providing vital nutrients to the lens and cornea.  
 
    1.1.2.2 Choroid 
 
The purpose of the extremely vascular, pigmented choroid is twofold (Mortazavi et al. 
2014). Its melanin, produced by melanocytes, absorbs stray light that would otherwise 
reflect from the sclera, while its concentrated blood and lymphatic networks deliver 
nutrition to the retina. Histologically, the choroid is divided into four sections, namely the 
suprachoroid lamina, stroma, choriocapillaris and Bruch’s Membrane (BM).The 
suprachoroid lamina is a fragile layer of pigmented connective tissue while the stroma 
mainly consists of medium- to large sized blood vessels. The choriocapillaris consists of 
3 
 
a solitary layer of fenestrated capillaries which constitute the majority of the choroid. 
The fenestrated endothelium of the choriocapillaris works in conjunction with BM and 
the retinal pigment epithelium (RPE) to form the outer part of the blood-retinal barrier 
(BRB) which functions to maintain a highly specialized milieu within the eye (Runkle et 
al. 2011). 
 
      1.1.2.2.1 Bruch’s membrane 
 
BM, the innermost layer of the choroid, is an acellular, pentalaminar structure primarily 
composed of extracellular matrix. As a transport medium, it functions to unite the RPE 
and choriocapillaris by exchanging biomolecules, nutrients and metabolic end-products 
between them. Structurally, it functions as a coil for the lens during accommodation. 
The BM suffers significant age-related alterations at a structural level causing reduced 
filtration-capability and loss of elasticity which contributes (pathologically) to macular 
and retinal disorders. These changes include collagen cross-linking, mineralization from 





  1.1.3 The retinal tunic 
 
The inner layer, or retinal tunic, consists of multi-layered neuronal tissue (Figure 1.2) 
containing photoreceptor cells that transduce the incoming electromagnetic light energy 
into electric nervous impulses. These action potentials are processed and carried along 
the ganglion cells of the optic nerve to the posterior pole of the occipital cortex where a 





Figure 1.2: An illustration of the retina depicting the different layers and cell structures.  
Reproduced and adapted from the website MyHumanBody.ca: 
http://www.corpshumain.ca/en/Vue_en.php 
 
The macula is an oval-shaped area, roughly 5.5 mm in diameter, and located 3.5 mm 
lateral to the optic disc, proximal to the midpoint of the retina. The darker discolouration 
of the macula on fundoscopy is due to its macular pigment (MP) concentration, 
particularly zeaxanthin. Centrally located within the macula is the fovea centralis, a 
small pit containing only closely packed cone cells specific for maximal visual acuity. In 
contrast to the rest of the retina, the macula’s underlying choroid capillary bed and 
pigment epithelial layer is much thicker. The thicker pigment epithelial layer leads to a 
higher melanin content which is of clinical significance for macular disorders. 
 
Morphologically, the retina sub-divides into ten distinct strata consisting of the RPE 
externally, and two synaptic or plexiform layers alternating between the photoreceptors, 
i.e. the inner nuclear layer and ganglion cells internally 
(http://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/). 
The two plexiform layers, namely the inner- and outer-plexiform layers, serve to create 
synapses for communication both laterally and vertically between adjacent layers. They 
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also contain non-fenestrated capillary endothelial cells that comprise part of the inner 
BRB. The photoreceptor layer contains the two specialized neuronal cells termed rod 
and cone cells. Their cell bodies are situated in the outer nuclear layer just internal to 
the photoreceptor layer. The rest of the cells divide into the inner and outer segments, 
comprising the photoreceptor layer. The inner segment (IS) is packed with mitochondria 
and various organelles essential for cell metabolism. The outer segments (OS) contain 
stacked double membrane discs embedded with visual pigments to initiate 
phototransduction. The OS of cone cells are cone-like in structure and contain iodopsin 
as the visual pigment. In contrast, the OS of rod cells are elongated and tubular in 
structure with rhodopsin as the visual pigment. Rod cells vastly outnumber cone cells in 
the retina at a ratio of about 20:1 and are extremely sensitive to light, enabling scotopic 
or night vision. Cone cells are exclusively responsible for colour perception and are 
densely arranged within the fovea centralis, the central pit inside the macula, to permit 
central vision, at high resolution (Kawamura et al. 2008).  
 
The inner nuclear layer contains amacrine, bipolar and horizontal cells which operate, 
both as a signal conduit between the photoreceptor and ganglion cells, and to improve 
the contrast sensitivity of the eye. The inner BRB is made up of the non-fenestrated 
retinal capillary endothelial cells within the plexiform layers of the retina. 
 
Ganglion cells, collectively, transmit processed visual data as action potentials along 
long axons through the optic nerve to the brain. Moreover, the photosensitive capability 
of ganglion cells contribute to the pupillary light reflex and help regulate sleep-wake 
circadian rhythms.  
 
    1.1.3.1 The retinal pigment epithelium (RPE)    
 
The basal layer of the retina, the RPE, is positioned between the photoreceptor retinal 
layer and the uvea. Its densely pigmented, monolayer of tightly packed hexagonal cells 
serves several functions, namely - light absorption, retinal storage and metabolism, 
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metabolic homeostasis, preservation of photoreceptor outer segment length and 
regulation of the immune privilege of the eye (Strauss et al. 2005). 
   
      1.1.3.1.1 Melanin 
 
Light entering the eye is predominantly absorbed by pigments, namely, melanin and 
MP. Ocular melanin enhances visual acuity by: (i) absorbing scattered light reflecting 
from the sclera, (which would otherwise create false signals), and (ii) diminishing photo-
oxidative stress. Melanin occurs in two different pigment cells; choroidal melanocytes 
and pigment epithelial cells, each with separate embryonic origins (Park et al. 2009). 
Pigment epithelial cells, in the RPE, contain mainly eumelanin which has a black-brown 
hue and has a comparable high density in the irises of all people. Conversely, choroidal 
melanin content differs significantly between different ethnic groups, with the highest 
concentrations occurring in Africans. Choroidal melanocytes, containing not only 
eumelanin but also pheomelanin which imparts a lighter reddish hue, maintain a 
constant melanin content throughout life. Unlike the choroid, melanin biosynthesis is 
absent in adult RPE cells, and the pigment decreases in this tissue with increasing age.  
 
      1.1.3.1.2 Pro-oxidative environment 
 
Additionally, melanin functions as an anti-oxidant and free radical scavenger within the 
pro-oxidative milieu of the RPE. This stressful environment results firstly from the strong 
concentration of light energy focused through the lens onto the retina, and secondly, 
from the high venous oxygen saturation in the choroid capillaries. The high oxygen 
saturation results in both the choroid’s high blood flow and low oxygen extraction which 
is a diminutive three percent when compared to the 50 % extraction of the retinal 
circulation (Linsenmeier et al. 2000). Beneficially, this high blood flow acts as a heat 
sink for all the heat generated from metabolic processes and light absorption, while 




Another compounding element adding to the pro-oxidative environment is the 
unremitting load of free radicals entering the RPE from the phagocytosis of shed 
photoreceptor outer segments (POS). As mentioned previously, the POS are the 
external sections of the photoreceptor generated from stacks of double pleated 
membranes containing light sensitive visual pigments. These POS membranes are rich 
in polyunsaturated fatty acids making them prone to peroxidation. Old outer segments 
are pinched off and engulfed by the apical processes of the RPE on a diurnal basis. 
Approximately 15 % of the POS are phagocytized by the RPE, and replaced, on a daily 
basis (Hollyfield et al. 1977).   
     
      1.1.3.1.3 Macular pigments 
 
The MP, lutein and zeaxanthin, are lipophilic carotenoids that function as anti-oxidants 
along with melanin. Besides quenching reactive oxygen species (ROS), they effectively 
protect the retina from damaging blue light due to their absorption spectrum, peaking at 
460nm. MP are found mainly within the inner plexiform and outer ganglion layers within 
the retina, with the highest concentration occurring within the fovea inside the macula 
(Ahmed et al. 2005). It is this distribution of MP to which the macula owes its yellow 
colouration. Since humans are unable to synthesize carotenoids, the concentration of 
the macular pigments is entirely diet-dependent.     
 
      1.1.3.1.4 Visual cycle 
 
Another vital recycling process within the RPE is the retinal visual cycle. The aim of this 
cycle is the circulation and metabolism of Vitamin A derivatives between the RPE and 
POS. 11-cis-retinal, a photoreactive chromophore, is a cofactor to the transmembrane 
protein, opsin, together forming the visual pigment rhodopsin, which is loosely packed 
within the central region of the POS (Buzhynskyy et al. 2011). Light induces 
isomerization of 11-cis-retinal to all-trans-retinal (ATR) which prompts a conformational 
transformation in opsin. This leads to G-protein coupled second messenger activation 




circular enzymatic pathways, ATR is re-isomerized to 11-cis-retinal within the RPE and 
returned to the POS via Retinal-binding protein 3, to replace the consumed 
chromophore.  
 
      1.1.3.1.5 ABCA4 gene and protein 
 
Integral to the retinal visual cycle is an outer segment rim protein, termed ATP-binding 
cassette, sub-family A, member 4 (ABCA4), which facilitates removal of ATR from POS 
following photobleaching. ABCA4, encoded by the ABCA4 gene on chromosome 1p22, 
is a member in a superfamily of ATP-binding cassette (ABC) transporters localized 
within disk margins of both rod and cone outer segments. As one of the biggest protein 
classes, ABC transporters hydrolyze ATP to transport various substrates across the cell 
membrane. Once activated, ABCA4 transfers its substrates, N-retinylidene-PE (NR-PE) 
and phosphatidylethanolamine (PE), from the POS lumen to its cytoplasmic side. PE is 
a class of phospholipids found in all human cells. NR-PE then dissociates into PE and 
all-trans retinaldehyde which is subsequently reduced to ATR by retinol dehydrogenase. 
ATR is then transferred to the RPE where it is converted to 11-cis-retinal by retinoid 
isomerase. Failure to remove NR-PE results in formation of a fluorophore salt, N-retinyl-
N-retinylidene ethanolamine (A2E), a toxic derivative of the visual cycle and primary 
component of lipofuscin. As a fluorophore, A2E sensitizes the retina to more blue light 
damage and its ionic properties result in further destabilization of cellular membranes 
(Shaban et al. 2002).  
 
       1.1.3.1.6 Lipofuscin 
 
Lipofuscin refers to the autofluorescent, intra-cellular material that accumulates within 
the RPE, and is composed of chemically altered deposits of partially degraded POS. 
RPE cells are post-mitotic and therefore unable to dilute the intracellular lipofuscin, 
which accumulates with increasing age. Accumulation is aggravated by the fact that 
lipofuscin aggregates have proven resistant to cellular enzymatic breakdown. The 
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highest concentrations of lipofuscin occur within the macular RPE, with the exception of 
the fovea. Surprisingly, an exponential rate of lipofuscin build-up occurs in the first two 
decades of life. Thereafter, the increase in RPE lipofuscin correlates linearly with 
increasing age. Lipofuscin build up leads to RPE cellular dysfunction through cellular 
engorgement and leaching of toxic oxidized molecules into the cellular cytoplasm 
(Kennedy et al. 1995).  
  
      1.1.3.1.7 Immune regulation 
 
Finally, the RPE contributes to the immune privilege of the retina by secreting several 
critical factors and by its tight junctions between neighbouring cells, contributing to the 
outer component of the BRB. The RPE contributes to the innate immunity of the retina 
by expression of Toll-like receptors which are conserved immune response molecules, 
able to sense pathogenic microbial molecules (Kumar et al. 2004). As a first line of 
defense against microbial invasion, RPE cells rapidly secrete pro-inflammatory 
cytokines such as interleukin (IL)-6 and IL-8.  
 
When required, the RPE can also down regulate the immune response by a variety of 
immune suppressive factors such as IL-11 and transforming growth factor-beta (TGF-β). 
TGF-β is a multifaceted cytokine involved in cell growth, immune response and 
extracellular matrix (ECM) synthesis. When activated, TGF-β has been shown to induce 
RPE cells to release factors like pigment epithelium-derived factor and vascular 
endothelial growth factor (VEGF). Pigment epithelium-derived factor acts as an 
antiangiogenic and neuroprotective factor, inhibiting pathological vascularization in 
apoptotic conditions. VEGF is active in angiogenesis and chemotactic signalling 
recruiting both granulocytes and macrophages. Part of the angiogenic function of VEGF 
is to increase matrix metalloprotease activity. Conversely, the RPE also secretes 
different types of tissue inhibitors of matrix metalloproteases (TIMP), which are thought 
to be critical for preservation of BM. This ability to secrete antagonistic factors, when 
needed, illustrates how essential the RPE is for a homeostatic environment in the retina. 
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Lastly, the RPE is also involved in the adaptive immune response by functioning as an 
antigen presenting cell (APC) (Holtkamp et al. 2001). 
 
1.2 Stargardt Disease 
 
Stargardt disease (STGD), of which there are three types, is one of the most frequent 
causes of juvenile macular dystrophy and was first described in 1909 by a German 
ophthalmologist, Karl Stargardt (Stargardt et al. 1909). STGD typically presents within 
the first two decades of life with an incidence of approximately 1:10 000, with a 
particularly high carrier frequency in the general population of about two percent 
(Blacharski et al. 1988).  Patients initially present with a severe debilitating central vision 
loss while maintaining their peripheral vision. There is also an associated loss of colour 
vision and reduced dark adaptation.  
 
STGD type 1, which is the predominant type in populations studied to date, is inherited 
in an autosomal recessive pattern and mostly associated with mutations in ABCA4. 
STGD type 3, conversely, is inherited in an autosomal dominant fashion and caused by 
mutations in ELOVL4 which encodes the ‘Elongation of Very Long Chain Fatty Acids 
Protein 4’. STGD type 4, which is inherited as an autosomal dominant condition, occurs 
as a result of mutations in the Prominin-1 (PROM1) gene. STGD type 2 is no longer 
used within STGD classification since the original mapping of the STGD phenotype in a 
family, to chromosome 13q34, was discovered to be incorrect.    
 
  1.2.1 Pathogenesis 
 
As described above, a defective ABCA4 protein leads to the accumulation of A2E and 
lipofuscin in RPE cells of the macula. This accumulation leads to lysosomal dysfunction 
and photo toxicity in the RPE. This results in RPE cell death which secondarily, triggers 
photoreceptor damage and ultimate vision loss (Cideciyan et al. 2004). Clinically, STGD 
is observed as yellow-orange flecks around the macula , with the characteristic “beaten-
bronze” appearance upon fundoscopy. A definitive diagnosis is made with a fluorescein 
11 
 
angiogram which shows a dark choroid with hyper fluorescence from the retinal flecks. 
The dark choroid is caused by the blocking of the choroidal fluorescence from the 
excessive RPE lipofuscin buildup. The causal gene for type 1 STGD, ABCA4, was 
identified in 1997 (Allikmets et al. 1997a). Surprisingly this gene was found to be 
expressed mainly within rod photoreceptors. 
 
More than 800 mutations have been found within ABCA4 since its discovery (Allikmets 
et al. 2007), although only 10 % of STGD patients are found to have frequent disease-
associated ABCA4 variants, and more than half these mutations have been reported 
once only (Zernant et al. 2011). Although most are missense mutations, a wide 
spectrum of genetic variants have been reported, ranging from insertion/deletions to 
uniparental disomies (Fingert et al. 2006). Additionally, ABCA4 is known to exhibit high 
allelic diversity of its coding region; this is illustrated through its nucleotide diversity 
being nine to 400 times higher than other macular disease genes which were similarly 
studied (Webster et al. 2001). Screening of ABCA4 has historically been inefficient with 
only one mutation found in 15 – 20 % of patients and no mutation in 15 % of patients 
(Zernant et al. 2011). Similar proportions were found when ABCA4 was screened using 
next generation sequencing and array-comparative genomic hybridization (aCGH) in an 
African American STGD cohort (Zernant et al 2014). Mutations in ABCA4 have also 
been shown to cause various other visual disorders including, cone-rod dystrophy 
(Cremers et al. 1998), retinitis pigmentosa (RP) (Cremers et al. 1998) and age-related 
macular degeneration (AMD). The first part of this study will focus on STGD, the 
juvenile form of macular degeneration, which is associated with mutations in ABCA4.  
 
ABCA4 is a large gene comprising of 50 exons, and mutation screening using 
conventional Sanger sequencing is arduous. A commercial microarray, the ABCR400 
chip, has been designed by Asper Ophthalmics in Estonia 
(http://www.asperbio.com/asper-ophthalmics) to simultaneously screen for all previously 
reported ABCA4 mutations/variations (n>600). The microarray chip, which is frequently 
updated, efficiently identifies 65 – 75 % of all disease causing ABCA4 alleles within 
each cohort screened. To date, on average, 40 % of a STGD cohort will have both 
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mutations identified (i.e. bi-allelic), with another 40 % having only one mutation and the 
remaining 20%, no mutations identified, when using the ABCR400 chip (Ernest et al. 
2009; Klevering et al. 2004; Allikmets 2007). This array has proven successful for 
screening Caucasian South African (SA) patients with STGD, and seven common 
ABCA4 mutations were found to occur frequently amongst the South African Afrikaner 
community (Roberts et al. 2012). The Afrikaner community is a Caucasian population 
that originated from European immigrants more than 300 years ago (September et al. 
2004). These endogamous immigrants stem mainly from Holland, Germany and France 
and have been associated with a number of heritable genetic disorders other than 
STGD (Gevers at al. 1987).  
 
In contrast to what has been found in the Caucasian population, the microarray 
screening has proven less successful for indigenous African SA patients with STGD. 
This is likely due to them having novel mutations, which are not tested for by the array.  
 
1.3 Age-related Macular Degeneration (AMD) 
 
AMD is a multi-factorial, neuro-degenerative disease of the macula in the elderly, set to 
become a major economic health burden due to the increase in global population and 
life expectancy rates. Symptomatically, it presents with a gradual loss of central vision 
which is essential for everyday activities such as reading and driving.  
 
  1.3.1 Epidemiology 
 
Globally, AMD is the fourth largest cause of blindness following cataracts, glaucoma 
and blindness of undetermined causes, and accounts for five percent of the global blind 
population (Jonas et al. 2014). Within the global elderly population (over 50 years of 
age) in the developed world, AMD is the leading cause of irreversible visual impairment. 
Epidemiological studies on AMD worldwide have mainly focused on Caucasian and 
Asian populations, with studies on African (-derived) populations occurring outside of 




Although, anecdotally, it is assumed to be a rarity among indigenous southern Africans, 
AMD has been reported to be a significant  cause of visual impairment in studies 
performed in populations in Kenya, Tanzania, Cameroon (Oye et al. 2007), Guinea, 
Zanzibar and Rwanda (Mathenge et al. 2007). Accurate comparison between studies is 
limited due to the use of different grading systems and the lack of retinal digital 
photography for all individuals. A recent cross-sectional study conducted on a Kenyan 
population, older than 50 years of age, using a modified version of the International 
Classification and Grading System for Age-Related Maculopathy and retinal 
photographs for those diagnosed, found the incidence of early and late AMD to be 11.2 
and 1.2 %, respectively (Mathenge et al. 2013). Multiple population-based studies have 
reported incidence differences in AMD between ethnic groups. Despite limitations and 
differing diagnostic criteria in these studies, they all confirm AMD to be less prevalent in 
Africans with incidence rates ranging between 0.7 and 2.7 %  compared to Caucasian 
incidence rates of between 2.1 and 10.9 % (Klein et al. 2006; Bressler et al. 2008; 
Leske et al. 2006; Erke et al. 2012). The difference in prevalence is also observed when 
Africans and Caucasians are studied from within the same geographical region 
(Friedman et al. 1999). This partly removes the environment as a confounding factor, 
suggesting that genetic protective factors may play a role in Africans, or that 
Caucasians are more genetically susceptible. 
  
Further studies also highlight the geographical effect on the frequency of early and late 
AMD in the same ethnic group (Klein et al. 2004). Early AMD is more prevalent in 
Caucasian populations from Norway and Iceland while late AMD is reported to occur at 
a higher incidence in populations in the USA, Australia and Holland (Klein et al. 2004) . 
Paradoxically, it has been reported that although early signs of AMD are similar among 
African and Caucasian populations, the incidence of early and late AMD is higher in 
Caucasians (Klein et al. 2004).  





   1.3.1.1 Ethnic anatomical differences 
 
Anatomical differences within the macula between ethnic groups have been 
hypothesized to influence susceptibility to AMD. These differences include: Iris colour, 
melanin content, lipofuscin and macular-pigment concentration. Iris colour, owing to 
pigment density in its anterior layer, determines the initial amount of light absorbed and 
therefore protects the retina from excessive light exposure and oxidative damage. This 
is evident in individuals with blue- or hazel-coloured irises, more common in 
Caucasians, who display significantly higher susceptibility to AMD (Nicolas et al. 2003).  
 
Melanin concentration in the RPE, which peaks within the macula, is similar among 
Caucasian and African populations and decreases with age. Choroidal melanin content 
is significantly greater in Africans compared to Caucasians (Hu et al. 2008).   
 
RPE-lipofuscin aggregation increases with age in all ethnic groups but considerably 
more so in Caucasians. This aggregation leads to thickening of the already thicker 
nerve fiber layer within the macula in Caucasians.  
 
The MP, lutein and zeaxanthin, play important roles in filtering blue light and quenching 
free radicals. Racial differences in MP distribution were investigated among healthy 
subjects and a definite increased density in central macular pigment was observed in 
Africans compared to other groups (Wolf-Schnurrbusch et al. 2007). 
   
  1.3.2 Risk factors 
 
AMD develops due to a complex interaction between environmental, genetic and aging 
factors. Aging is the greatest risk factor for developing AMD. Various age-related 
changes contribute to AMD, including loss of rod photoreceptors and RPE atrophy due 
to lipofuscin build up (Brink et al. 2002). Among modifiable factors, smoking plays the 
most significant role in AMD development (Smith et al. 2001). Smoking contributes to 
oxidative damage at the level of the RPE by freeing large quantities of ROS and other 
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toxic substances. This leads to accelerated atherosclerotic plaque formation and 
endothelial dysregulation within the RPE. Other modifiable factors include dietary 
supplementation which has been shown to alter AMD progression, to a certain extent.  
These dietary supplements include vitamins B6, B12, C and E, zinc and the macular 
pigments, lutein and xeazanthin (Age-Related Eye Disease Study Research Group et 
al. 2001). Clinical factors that increase susceptibility include hypertension, elevated 
body mass index (BMI) and hypercholesterolemia (Hogg et al. 2008).   
 
  1.3.3 Pathogenesis 
 
Drusen, the hallmark of AMD, are extracellular aggregates primarily composed of lipid 
peroxidation products, AGE, protein crosslinks and various complement factors formed 
by the constant oxidative stress in the macula (Crabb et al 2002). Drusen accumulates 
with age, between the basement membrane of the RPE and BM, and is ubiquitous 
among individuals over 40 years of age. Clinically, drusen may be sub classified into 
hard and soft drusen. Hard drusen can be seen as small, hard sub-RPE yellowish 
deposits under 63 micrometers (µm) in diameter with well-defined borders. Small 
pockets of hard drusen deposits in the periphery can be seen as part of the normal 
aging process and are not considered pathological. Soft drusen are wider than 63 µm 
with indistinct margins, tend to coalesce to become confluent and represent localized 
detachment of the RPE.  
 
As mentioned previously, the comparability of AMD studies is limited due to the different 
classification systems that have been used, ranging from the Rotterdam Eye Study 
Staging System (Klaver et al. 2001) to the International Classification and Grading 
System by the International Age-related Maculopathy Epidemiological Study Group 
(Bird et al. 1995). Although clinically categorized into four groups, the disease is 
generally divided into early or late AMD. Early, also termed dry, AMD is diagnosed with 
the presence of drusen and RPE abnormalities, including geographic atrophy (GA). 
Abnormalities of the RPE include hyper or hypopigmentation which signify mobilization 
of the pigment and loss of RPE cells. GA is defined as an oval area of 
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hypopigmentation exceeding 175 µm where choroidal vessels are more visible in 
surrounding areas. GA is characterized by an area of RPE cell death with overlying 
neural retina atrophy and leads to gradual visual loss.  
 
Twenty percent of individuals with GA progress to late, also termed wet, AMD which is 
characterized by choroidal neovascularization (CN). CN, mediated by VEGF, is a 
process of vasculogenesis into the RPE and sub-retinal space through openings in BM. 
These abnormal vessels leak fluid and haemorrhage, leading to macular scar formation 
and sudden onset of vision loss (Bressler et al. 2009). Wet AMD is defined as the 
presence of any of the following: Serous (or haemorrhagic) sensory retinal detachment; 
neo-vascular membrane formation; pigment epithelial haemorrhages, or sub-retinal 
fibrin-like deposits  
 
  1.3.4 Genetics of AMD 
 
AMD has been extensively studied for associated genetic and epigenetic factors. In 
contrast to other complex diseases, half of the genetic heritability of AMD can be 
accounted for by a few genetic loci (Swaroop et al. 2007). This is further illustrated 
through twin and familial studies, where risk of AMD in first-degree siblings of AMD 
individuals is double that for siblings of unaffected individuals (Swaroop et al. 2007).  
Similarly, concordance among mono-zygotic twins further supports an increased risk 
associated with a family history of AMD. Historically, identification of susceptibility loci 
relied on linkage studies in smaller families, and consistently showed positive signals on 
chromosomes 10q26 and 1q25-31, suggesting these as loci for susceptibility factors 
(Swaroop et al. 2007). Detection of AMD-associated variants near the Complement 
Factor H (CFH) locus on chromosome 1q31 led to the discovery of multiple associations 
with other complement genes such as C2, C3, CFB and CFI (Anderson et al. 2010).  
 
The association on chromosome 10q26, has led to the discovery of three potential 
susceptibility genes, namely: LOC387715/ARMS2 (age-related maculopathy 
susceptibility 2), HTRA1/PRSS11 (high-temperature requirement factor A1) and 
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PLEKHA1. The ARMS2 gene produces a protein of (as yet) unknown function, and 
which is present in the retina and placenta (Andreoli et al. 2009). Recently, the most 
significant discoveries have emerged from genome-wide association studies (GWAS). A 
meta-analysis of AMD-GWAS performed through collaboration of 18 centers revealed 
19 different AMD susceptibility loci which fit into previously known pathways, and seven 
novel loci containing novel genes (Fritsche et al. 2013). Pathways associated with the 
identified susceptibility loci have been consistent with the proposed pathogenesis of 
AMD. These pathways consist of the complement system, oxidative stress, extra-
cellular matrix, lipid regulation, and angiogenesis-signalling.  
   
    1.3.4.1 Protective alleles 
 
After years of genetic research since the first gene, CFH, was associated with AMD, the 
full genetic landscape of AMD still remains unresolved. The susceptibility to AMD 
consists of an interaction between both risk and protective alleles, along with non-
genetic factors such as the environment and increasing age. Some candidate genes, 
like CFH and apolipoprotein E (ApoE), have even been shown to harbor both risk and 
protective alleles (Baird et al. 2004). Largely, studies have focused on identifying 
protective alleles in a specific ethnic group. Within Caucasian populations, a decreased 
frequency of the ApoE ɛ4 allele within the AMD group compared with a control cohort 
provides support for the hypothesis of ApoE ɛ4 as a protective gene/allele for AMD. 
Another investigation within Caucasian AMD family-based and control data sets found 
SNPs in CFB and CC2 conferring a decreased susceptibility to AMD (Spencer et al. 
2007). Occasionally, a protective factor is shown to act across multiple ethnic groups 
like the protective CFH haplotype that is associated with a delCFHR1/CFHR3 mutation 
(Hageman et al. 2006). 
 
Identifying a protective allele provides insight into possible gene and pathway 
associations that ultimately lead to a better understanding of the protective role of the 
allele in AMD within the ethnic group concerned. This is illustrated with the first 
demonstration of an Alu insertion element in the angiotensin-converting enzyme (ACE) 
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gene, providing protective effects for dry AMD (Hamdi et al. 2006). Although the 
correlation between blood levels of ACE and the pathophysiology of AMD is unknown, 
these findings help stimulate future research concerning AMD pathways (Hamdi et al. 
2006). Similarly, the Q192R polymorphism in PON1 showed decreased susceptibility for 
AMD, although the mechanism is still unknown (Pauer et al. 2010). In 2010, a GWAS 
found two intronic SNPs, rs429608 in SKIV2L and rs2679798 in MYRIP, as protective 
variants for AMD.  The function of the protein that SKIV2L encodes for is yet to be 
confirmed and it shares its cytogenetic location on chromosome six with other 
complement genes. Furthermore, MYRIP is involved in RPE melanosome trafficking 
and maps to chromosome 3p21 (Kopplin et al. 2010). 
 
Considering the large genetic heritability of AMD and the significant difference in 
prevalence of AMD between Africans and Caucasians, it is reasonable to hypothesize 
that genetic protective factors exist within the African population. As discussed earlier, 
the anatomic and environmental differences between these ethnic groups have been 
investigated to explain the discrepancy in prevalence, but none have provided sufficient 
evidence. Other clinical factors such as diabetes, BMI and inflammatory markers were 
analyzed among AMD individuals from different ethnic groups in the Multi-Ethnic Study 
of Atherosclerosis (MESA) cohort and also failed to explain these differences in 
prevalence (Klein et al. 2008). These results substantiate the need to explain these 
differences genetically. In a multi-ethnic study, Klein et al. (2008) tried unsuccessfully to 
use the CFH Y402H CC genotype to explain the differences in AMD prevalence 
between Caucasians and Africans. This adds to the solitary study done in Africa 
seeking an association between the Y402H variant and dry AMD, which was based on a 
limited cohort and failed to show a significant correlation (Ziskind et al. 2008). 
 
No previous studies have been performed on the various ethnic African groups within 
SA for possible genetic protective factors against AMD. Firstly, African control genomic 
data from a local database were investigated to find SNP loci within AMD candidate 
genes with significantly higher frequencies when compared to a Caucasian control 
group. It is hypothesised that of these SNPs, any showing a decreased allele frequency 
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within an African AMD cohort when compared to the African control group are likely to 
be associated with a protective factor, either in the gene it resides in, or a genomic 
locus with a significant linkage disequilibrium (LD).  
 
1.4 Aims and objectives 
 
This pilot project aims to investigate the two macular degeneration disorders described, 
namely STGD and AMD, in the previously understudied indigenous SA population. The 
two disorders will be interrogated in two separate parts of the project. 
 
The first part of this study aims to screen an African STGD cohort for novel mutations in 
the STGD-causal gene, ABCA4. The objective is to sequence the entire coding region 
of the ABCA4 gene, comprising 50 exons, in three STGD individuals representing the 
three common haplotypes, in which mutations have not hitherto been identified. This will 
be done in order to identify pathogenic mutations which may account for a significant 
proportion of STGD in this population group.  
 
The second part of this study aims to search for protective genetic factors that may 
explain the reduced susceptibility to AMD observed within the indigenous African 
populations in SA. The objective is to genotype variants within known AMD candidate 
genes that are more frequent in African populations compared to Caucasian 
populations. Any of these variants then found to exhibit a reduced frequency within an 
African AMD cohort, could represent candidate protection factors. Identification of 
genetic protection factors, and the functional roles they play, could ultimately have 









Chapter 2: Materials and Methods 
 
2.1 Patient recruitment 
 
  2.1.1 UCT Retinal Registry Database investigation 
 
The Retinal Degenerative Disorders (RDD) database currently comprises phenotypic 
and demographic details of subjects with RDDs, as well as details of biological material 
available, and molecular genetic investigations carried out to date.  A specific emphasis 
was on extracting information on individuals and families admitted to the study with 
either STGD or AMD phenotypes.  Furthermore, an attempt was made to obtain data on 
the methodologies used in investigations to date, and to determine whether there was 
any bias in the ethnicity of individuals in whom disease-causing mutations had been 
detected.  Following this, specific samples/subjects in which no disease-causing 
mutations had been detected to date were selected for further molecular investigations.  
 
These subjects had already been recruited under the broader RDD project with 
informed consent obtained according to the tenets of the Declaration of Helsinki (2008). 
Ethics approval for this study was obtained from the University of Cape Town (UCT) 
Research Ethics Committee (UCT HREC REF: 432/2013) linked under the umbrella 
RDD project (UCT HREC REF 226/2010). All individual samples chosen were already 
stored within the Retinal Registry in the Division of Human Genetics at UCT, along with 
clinical information including ethnicity, date of birth, age of onset (AOO) and 
ophthalmological diagnosis. The three individual STGD patients were deduced as 
representative of the common haplotype groups will be referred to as the test samples 
hereafter. The remaining African STGD samples known to carry one or more of the 






  2.1.2 PHASE Haplotype analysis for STGD sample selection 
 
Interrogation of the RDD database showed the ABCR400 microarray chip to be 
relatively unsuccessful in identifying mutations within the African STGD cohort (i.e. only 
11% of those screened had both disease-causing alleles identified – compared to 58% 
of Caucasian STGD patients.).  It was therefore decided to investigate the part of the 
indigenous southern African cohort without full molecular diagnosis for possible 
common ABCA4 haplotypes. The decision to use haplotype analysis and not full cohort 
exome sequencing was in part due to resource constraints within this research setting. 
A haplotype refers to a combination of genotypes/alleles that associate statistically and 
are inherited en bloc or together. Novel ABCA4 mutations, if present, could be expected 
to track with common haplotypes within the African STGD cohort. Therefore, screening 
of the individuals containing the common haplotypes presents a more cost-effective 
manner in which to elucidate these possible novel mutations.     
 
Haplotype analysis was performed on the 32 unrelated patients within the African STGD 
cohort who had only one or no ABCA4 mutations identified. Firstly, all genotype data of 
the 32 patients obtained from the ABCR400 microarray chip screening done previously 
(unpublished data) by Asper Ophthalmics (http://asperbio.com/asper-ophthalmics) was 
collected. Thereafter, all variants for each of the 32 patients occurring within ABCA4 
were extracted. These variants were further reduced to only those variants occurring in 
all of the 32 patients as different versions of the ABCR400 microarray had been used 
for the cohort in past years. This equated to a total of 17 SNPs shared among all 32 
patients within ABCA4 (Appendix 7).  
 
Information containing number of individuals, number of SNPs, chromosomal location of 
each of the 17 variants in ascending order and genotypes were organised onto an Excel 
Spreadsheet (Microsoft Office Home and Student 2010) (Redmond, WA, USA) 
according to the basic format within the PHASE (Stephens et al. 2001) guide. Once 
formatted, the sheet was changed to an input file (.inp) before it was run through the 
PHASE (Stephens et al. 2001) program using the command prompt, after which the 
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output file was produced within the same directory. This work, although presented here 
for a fuller understanding of what was done, was carried out by another member of the 
RDD research team, Ms Lisa Roberts, prior to the current work being carried out.  
 
   2.1.3 AMD sample selection 
 
In order to increase the AMD cohort size within the Retinal Registry, additional patients 
were recruited in collaboration with ophthalmologists in the Department of 
Ophthalmology at Groote Schuur Hospital in Cape Town. Ethics approval was granted 
by the UCT Research Ethics Committee (UCT HREC REF: 432/2013). A Confirmation 
of Diagnosis form (Appendix 6) was designed according to the International 
classification and grading system of AMD along with inclusion and exclusion criteria. 
Each consenting patient meeting the inclusion criteria underwent a 30° fundus 
photograph and a basic ocular examination, including a careful 78D fundal assessment 
by a registered ophthalmologist. After completion of the RDD Molecular Request form 
(Appendix 6) containing demographic, family and diagnostic information, 8ml (2 x 4ml) 
venous blood was collected in Ethylenediaminetetraacetic acid (EDTA) tubes. These 
samples were subsequently de-identified and added to the Retinal Registry within the 
Division of Human Genetics Database.  
 
  2.1.4 Selection of SNPs in candidate AMD genes 
 
The aim of the second part of this study was to identify the possible protective genes 
associated with a decreased susceptibility for AMD in the African population in SA. In 
order to do this, data on allele frequencies was accessed from a study in which high 
density genome-wide SNPs had been assayed on five indigenous Southern African 
populations, including Zulu, Xhosa, Sotho/Tswana, Herero and San (Chimusa et al. 
2015). Similar data in the public domain, from Caucasian populations (of which South 
African Caucasians were presumed to be a subset) were then compared for SNPs that 
displayed significantly high allele frequency differences in genes previously associated 
with AMD. An African AMD cohort was then genotyped for these selected SNPs and 
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those showing significantly decreased allele frequencies compared with the African 
control population were hypothesised to associate with a protective genetic factor. If 
multiple SNPs associated with the same gene it could be theorized that this gene plays 
an important protective role in the indigenous African population in SA. 
 
Firstly, an up–to-date list of 24 genes associated with AMD (Appendix 4) was extracted 
from ‘Genetics Home Reference' (http://ghr.nlm.nih.gov/condition/age-related-macular-
degeneration/show/Related+Gene(s)) (Updated: June 2011). The variants in these 
genes were extracted from data previously generated by our laboratory (Chimusa et al. 
2015).  This data comprises indigenous SA African control groups genotyped with the 
Affymetrix (Santa Clara, CA, USA, 1992) Genome-Wide Human SNP Array 6.0. 
Effectively the database contains allelic frequencies for various ethnic groups namely: 
Zulu (n=17), Xhosa (n=28), Sotho (n=25), Herero (n=25) and Khoisan (n=24).  
 
This local SNP 6 database contains more than 906 600 SNPs across the genome 
obtained from the Genome wide Human SNP array 6.0 by Affymetrix (Santa Clara, CA, 
USA, 1992). Data from the database was mined by using R (R core team, Vienna, 
Austria, 2013) (http://www.R-project.org/). The Caucasian control group was obtained 
from 1000 Genomes Browser (McVean et al 2012) 
(http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) (Build 14, Oct 2013) using 
the BioMart data mining tool (Kinsella et al 2011) in Ensembl (Flicek et al 2014) 
(http://www.ensembl.org/biomart/martview/0619df929ccd736db0908ca9d26d23e9). The 
group used to represent the Caucasian control group included Utah residents with 
Northern and Western European ancestry (n=99). SNP data used for this specific study 
included all SNPs located in the selected AMD genes that were also present in both the 
1000 Genomes (McVean et al 2012) Caucasian population and the local SNP 6 
database. From these approximately 1600 variants, all those SNPs with a ten-fold 





This totalled 69 different variants located in 12 of the 24 selected AMD genes. The 69 
variants were then further reduced by selecting only those SNPs that occurred in all the 
different ethnic groups within the SA African control group. From these, 10 SNPs were 
chosen from three different genes involved in proposed pathways that would support a 
plausible protective genetic role in the indigenous southern African population.      
 
2.2 DNA extraction and determination of integrity 
 
All samples recruited for the AMD cohort had DNA isolated by assigned researchers 
within the Division of Human Genetics at UCT using a modified salting out technique 
(Miller et al. 1988). Over time DNA samples fragment into smaller pieces due to freeze-
thaw cycles and nuclease contamination, therefore it was necessary to determine the 
quality of all samples before further genetic analysis. 
 
  2.2.1 Spectrophotometry 
 
Spectrophotometry measures DNA concentration and purity from contaminants such as 
protein and inorganic solvents. DNA concentration is calculated by optical density (OD) 
based on the absorbance of ultra-violet (UV) light by the sample at 260 nanometers 
(nm). The OD of the sample is converted to ng/µl using the Beer Lambert Law which 
states that absorbance is proportional to concentration at a specific wavelength. As 
proteins absorb UV light at a wavelength of 280 nm, the ratio of absorbance at 260 nm 
and 280 nm was used to exclude protein contamination. Values between 1.7 and 2.0 
indicate minimal protein contamination. A second measure of purity is the ratio of 
absorbance at 230 nm and 260 nm. Values under 1.8 indicate the presence of 
contaminants such as EDTA and phenol.      
 
The NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies Inc., Wilmington, 
United States of America [USA]) was used to perform spectrophotometry on all 
samples. Each sample measurement was repeated to obtain an average concentration, 
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used subsequently for dilutions to 100 nanogram (ng)/microliter (µl)) using SABAX 
distilled H2O (dH2O) (Adcock Ingram, Johannesburg, SA). 
 
  2.2.2 Agarose gel electrophoresis 
 
All samples were subjected to agarose gel electrophoresis to determine DNA integrity. 
Gel electrophoresis is a separation method used to determine DNA molecular size. 
When voltage is applied across a gel, DNA migrates to the anode due to its negatively 
charged phosphate backbone. The rate of migration is directly proportional to size; 
hence smaller DNA fragments migrate faster. Smeared patterns indicate fragmentation 
while a distinct, high-molecular weight band points to an intact specimen.  For accurate 
resolution, a two percent weight/volume (w/v) agarose (SeaKem® LE, Lonza, 
Switzerland) (Appendix 1) gel was prepared and treated with Ethidium Bromide 
(EtBr)(Sigma, ST Louis, MO, USA)(1 ng/µl). Wells were loaded with 200ng of the DNA 
sample and three µl loading dye (Appendix 1) to add density and facilitate observation. 
Adjacently, GeneRuler™ 100 base pair (bp) Plus DNA Ladder (Thermo Scientific, 
Waltham, MA, USA) (Appendix 2) was loaded to provide a set of size standards for 
comparison.  
 
Once loaded, the gel was electrophoresed within TBE (891.8 millimolar (mM) Tris, MW 
121.34; 889.4mM Boric Acid; 19.9mM EDTA, pH8) (Appendix 1) at 120 volt (V) and 90 
milliampere (mA) for 25 minutes (min). DNA visualization and image capturing was 
performed using the Uvipro Gold transilluminator (UVITec, Cambridge, UK) and UVIpro 
software v12.3 for Windows(Copyright 1999-2005). All subsequent agarose gel 
electrophoresis were carried out as per these described conditions, unless otherwise 







Figure 2.1: An example of an electrophoresis gel photograph depicting the DNA 
integrity of seven of the 14 haplotype samples. Lane MW: Molecular weight marker 
(GeneRuler™ 100bp Plus DNA Ladder; Thermo Scientific, Waltham, MA, USA). All 
samples showed a distinct, high-molecular weight band except Lane 6 which showed a 
smeared pattern indicating DNA degradation.  
 
2.3 Primer Design 
 
  2.3.1 Gene Annotation 
 
All gene sequences required for genetic analysis were annotated with the Annot v9 
programme designed by Dr. G. Rebello (April 2006). These include ABCA4, TIMP3 and 
HMCN1. In the case of TIMP3, whenever a SNP fell outside of the gene boundaries the 
sequence range upstream or downstream of the gene was increased to accommodate 
the SNP location. Two websites were used to obtain the full genomic sequence, 
namely: National Center of Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) and Ensembl (Flicek et al 2014) 
(http://www.ensembl.org/). Annotation accurately displays intron-exon boundaries, the 
most recent updated version of SNPs and genomic numbering of the gene sequence. 
The annotated sequence was used for sequence alignment, variation screening, primer 





46441 cagggcaagt cgcatccttt gtttctctga tgaggccatt actgagag^tc actgtggcat 
      (46489)(a/c)(dbSNP:rs17111014) 
46501 tttgctacta atgatgagct tgttattggt g^gggtacagc ctattaattt aggttattca 
      (46532)(g/a)(dbSNP:rs2275035) 
46561 tcaaatcctc cagcatggag ttgaatgaga catgtgatgt ggatacacta atgactatat 
ABCA4-Exon9 (46675-46814 -> 140bp)                         TOP 
46621 tgagttacaa gcaatgggga gtttctgtaa aatctgtccc ttgtctcctg gcagCATCCT 
46681 TTTGTAATGC ATTGATCCAG AGCCTGGAGT CAAATCCTTT AACCAAAATC GCTTGGAGGG 
46741 CGGCAAAGCC TTTGCTGATG GGAAAAATCC TGTACACTCC TGATTCACCT GCAGCACGAA 
46801 GGATACTGAA GAATgtaaga tcccagctgg gcttgccttg tgtaccctgg acctcccaga 
46861 agtgtgtgtg t^gtgtgtgtg tgtgtgagag agatgtgcct tcctggtagc acatctcatg 
      (46872)(-/ca)(dbSNP:rs5776201) 
 
Figure 2.2: An example of the annotated ABCA4 showing a region of exon nine. Exonic 
regions are indicated by uppercase letters and intronic regions by lowercase letters. 
SNP positions are indicated by a circumflex accent to the left of the nucleotide with 
information pertaining to nucleotide number, genotype and reference number within 
dbSNP shown below the line.  
  
  2.3.2 External Primer design 
 
Primers are single-stranded synthetic oligonucleotides that bind externally to a specific 
region of choice in order to amplify that region by polymerase chain reaction (PCR). 
Primers were designed to flank at least 10-15 bp either side of each exon to include 
splicing regions. External primers were designed using NCBI/Primer-BLAST (Ye et al 
2012) (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) which is a combination of Primer 
3 (Untergasser et al 2012) (Whitehead Institute for Biomedical Research, 
2004)(http://www.frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and NCBI BLAST 
(Camacho et al 2008) (Bethesda, USA) (http://www.ncbi.nlm.nih.gov/). Input data 
consisted of the genomic sequence of interest in FASTA format, retrieved from the gene 
annotation. The following parameters were considered when using the NCBI/Primer-
BLAST (Ye et al 2012) program to maximize specific DNA amplification: 
1. Primer length: Optimal primer length is 18-25 bp for adequate specificity 
2. GC content: Preferably between 40 and 60 %. 
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3. Primer melting temperature (TM): Reverse and forward primers with similar TM 
within the range of 52 degrees Celsius (°C) -62°C were chosen. 
Suitable primers within these parameters, and showing limited mismatches to 
unintended targets within the human genome were then analyzed with IDT (Integrated 
DNA Technologies) SciTools OligoAnalyzer 3.0 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) to screen for 
secondary structures. These structures were assessed on their stability, represented by 
the Gibbs free energy (∆G), and include hairpins, homodimers and heterodimers. 
Primer pairs were excluded if dimer formation resulted in a ∆G of less than minus five 
and especially if it contained three prime end dimers and/or hairpins.  
 
For each of the 50 exons of the ABCA4, external primers had been designed previously 
by researchers in the Division of Human Genetics at the University of Cape Town (UCT) 
(Appendix 5). From these external primers, working stocks of 20µM were diluted with 
SABAX dH2O (Adcock Ingram, Johannesburg, SA) and stored at -4°C. Before 
commencing with optimization, each of the 50 primer pairs was evaluated for suitability 
according to the above criteria.  
 
New external primers were designed according to the above criteria for exon nine of 
ABCA4 due to an inability to optimize the PCR with the previously designed primers 
(Table 2.1). For each of the ten candidate SNPs in previously identified AMD-associated 
genes, showing high allelic frequency differences between Black and Caucasian 
populations, a new external primer pair was designed (Table 2.2). Gene regions 400 bp 
downstream and upstream from each SNP of interest were interrogated for the optimal 
primer pair. Whenever a SNP had more than one suitable primer pair, the amplicon size 
of other SNPs were considered. This assured that SNPs grouped within the same 
multiplex reaction had amplicon sizes that could easily be differentiated when 
performing agarose gel electrophoresis. All external primers were purchased from IDT 





Table 2.1: Information pertaining to the external primer pair for ABCA4 exon nine  
 
Exon        Primer       Length             Primer sequence                   Size 
                Forward          20            5´-ttacaagcaatggggagttt-3´                    
                Reverse          20            5´-agagaattgtgaacccttcc-3´                    
 
Table 2.2: Information relating to the external primer pairs for 10 SNPs in candidate 
AMD genes 
 
SNP/Gene      Primer    Length           Primer sequence                 Size 
                       Forward      20         5´-agacccgacaggactttgta-3´            
                       Reverse      20         5´-gtttacgacgaagcccatct-3´      
                       Forward      20         5´-agactcaccccattcctgag-3´            
                       Reverse      20         5´-gagcaatcctgaaagccaga-3´ 
                       Forward      20         5´-acatcaggagacccagtttt-3´             
                       Reverse      20         5´-gaagcccagagcacatttat-3´ 
                        Forward     20         5´-attcagcatgtcagagtcag-3´             
                        Reverse     20         5´-aggatcatacactgtggctt-3´ 
                        Forward     20         5´-cttggggtgaagtaaatggt-3´               
                        Reverse     20         5´-tcttgtgtcatgtgtaggct-3´ 
                        Forward     20         5´-caacctggcagaatccttag-3´              
                        Reverse     20         5´-attcccaaaagaaagcgtgt-3´ 
                        Forward      20        5´-cctgccaacctcacttagta-3´               
                        Reverse      20        5´-ttcttacccagcatcttcca-3´ 
                        Forward      20        5´-ctcatcccagaagtgacaca-3´            
                        Reverse      20        5´-aggaaaagtcaggtcagtgg-3´ 
                        Forward      21        5´-agtcttccatgttctctctgc-3´               
                        Reverse      20        5´-cgtagcattggggtgacaca-3´ 
                        Forward      20        5´-aagttggcaggagcacaaga-3´          
                        Reverse      20         5´-tgtttatggcactggggcaa-3´ 
   
9 467 
rs.17110714 
 ABCA4 581 
rs.17110878
     ABCA4  203 
rs.6703052 
     ABCA4      195 
rs.487906  
    ABCA4        511 
rs.9621578 
   TIMP3        299 
rs.9621622  
   TIMP3       354 
rs.5998713
   TIMP3        169 
rs.1555494  
   HMCN1       272 
rs.1407428 
    HMCN1         571 
rs.6425006 
   HMCN1         327 
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2.3.3 Internal Primer design 
 
One internal primer was designed for each of the ten SNPs in candidate AMD genes 
(Table 2.3), along with the above mentioned external primers, for SNaPshot genotyping. 
The three prime tail of an internal primer binds a single base upstream or downstream 
from the SNP of interest, after which primer extension occurs with a single fluorescently 
labelled dideoxynucleotide triphosphate (ddNTP). This limits the choice of primer design 
to either the sense or antisense sequence immediately preceding the SNP. The 
presence of another SNP within either flanking sequence precluded it from selection. 
Final selection was based on the following parameters: 
1. Primer length: A range of 13bp to 42bp with an ideal length of 25bp.  
2. GC content: Between 20 and 80 % is acceptable. Ideally between 40 and 60 %. 
3. Primer TM: Primers multiplexed together should have similar melting 
temperatures. 
4. Length modification: Primers multiplexed together need to differ by four to six 
nucleotides in order to distinguish between final SNaPshot products. 
5. Secondary structures: Homodimers with less than minus nine ∆G and hairpins at 
high melting temperatures with involvement of the three prime end were deemed 
unacceptable.   
 
The web based tool, IDT SciTools OligoAnalyzer 3.0 was used to select primers 
according to the above mentioned parameters. The Local BLAST application in BioEdit 
(Hall 1999) Sequence Alignment Editor v.7.0.5.2 (Ibis Biosciences, California, USA) was 
used to create a database containing the sequences of all SNP amplicons to be used 
for SNaPshot analysis. To assess for any non-specific binding to other amplicons within 
each multiplex reaction, each internal primer was blasted against the created database. 
Finally, all internal primers were aligned against each other using the web-based 
version of AutoDimer 1.0 (Vallone et al. 2004) 
(http://yellow.nist.gov:8444/dnaAnalysis/primerToolsPage.do) to ensure minimal 
dimerization within multiplex reactions. A text file with all the internal primer sequences 
was uploaded as input data. All default values were used except the total score required 
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which was set at three. This setting limits the output file to primer interactions that score 
three or more.  Dimer formation is expected when internal primers bind at more than 
four consecutive nucleotide positions and when they specifically bind at the three prime 
end. Analysis in AutoDimer was repeated for each chosen internal primer once a 
random sequence five prime tail was added. Random tail sequences were generated 
using Sequence Manipulation Suite Version 2 (Stothard, 2000) 
(http://www.bioinformatics.org/sms2/).  
 
Table 2.3: Internal primers for ten SNPs and the associated information. 
 
     SNP           Primer     Length                             Primer sequence * 
rs6703052      Forward       41 
rs17110714    Forward       28      
rs17110878    Forward       23                 
rs487906        Reverse       35        
rs9621578      Reverse       25              
rs5998713      Reverse       39 
rs9621622      Reverse       25 
rs1407428      Forward       33 
rs1555494      Forward       31 
rs6425006      Forward       37 
 
*The sequence in bold represents the sequence designed to anneal to the 
complementary genomic DNA sequence. The rest of the sequence is the random 












5´-acagtgatataaagggaggctaagc tttggatt -3´ 
5´-gtaacaaatcgagacaagacaggcaa aggaaatcaag -3´ 
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2.4 Polymerase Chain Reaction 
 
PCR involves the exponential amplification of a specific region of interest on any DNA 
sequence. The process firstly requires a pair of oligonucleotide primers complementary 
to a short sequence at both the five prime and three prime end of the target sequence. 
DNA polymerase, a heat resistant enzyme, then synthesizes a new strand of DNA 
complementary to the delineated target sequence using deoxynucleotide triphosphates 
(dNTPs). The process is repeated for 30 cycles through three different incubation 
temperatures, namely denaturation, annealing and extension, on a thermal cycler. The 
annealing temperature within the Standard PCR conditions changes depending on the 
length and composition of the specific primer pair for that exon. Optimization 
experiments for each exon were performed using Standard PCR cycling conditions and 
a Standard PCR reaction mixture as shown in Table 2.4 and 2.5 respectively, unless 
otherwise stated. Amplification was confirmed by agarose gel electrophoresis as 
described in Section 2.2.2. These reactions were performed on the GeneAmp® PCR 
System 9700 (Applied Biosystems, California, USA) unless otherwise indicated.  
 
Table 2.4: Standard PCR Cycling conditions 
 
Number of Cycles            Process                Temperature (°C)    Duration 
            1                   Initial Denaturation               95                       5 min 
  
                                    Denaturation                    94                       30 sec 
           30                        Annealing             exon/SNP specific       30 sec 
                                      Elongation                      72                        40 sec 
  







Table 2.5: Standard PCR reaction mixtures 
 
                      Reagents                                   Final Concentration 
                 Forward Primer                                           10pmol 
                 Reverse Primer                                           10pmol 
      dNTP’s (Bioline, Michigan, USA)                            200µM 
   Colourless GoTaq™ Reaction Buffer 
(Promega, Madison, USA)(1.5mM, pH8.5)                      1 x 
          GoTaq™ DNA polymerase 
          (Promega, Madison, USA)                                  0.5 units 
 
  
  2.4.1 Multiplex PCR 
 
Multiplex PCR is an alternative PCR method whereby two or more loci are concurrently 
amplified in the same reaction. Advantages compared to singleplex PCR include both 
reduction in laboratory costs and time.  All ten SNPs in candidate AMD genes were 
divided into three multiplex groups based upon amplicon size and primer compatibility 
(Table 2.6). All amplicons within each multiplex were selected to ensure a difference of 
at least 80 bp in size between them in order to improve visualization on agarose gel 
electrophoresis. Prior to multiplex grouping all internal primers and amplicons were 
checked for compatibility with AutoDimer 1.0 (Vallone and Butler 2004) to reduce the 
formation of unwanted heterodimers.  
 
Multiplex PCR was conducted according to standard PCR reaction mixtures and cycling 
conditions as described in Table 2.4 and 2.5. Singleplex PCR, whereby a single loci is 
amplified in one reaction, was used for SNPs in candidate AMD genes within a multiplex 
group that eluded amplification and samples to be subsequently sequenced for 





Table 2.6: Information relating to multiplex grouping of 10 SNPs in candidate AMD 
genes 
 
Group                                 SNP                                 Amplicon size 
     1                               rs.17110714                                  581 
                                      rs.9621622                                    354 
                                      rs.1555494                                    272 
                                      rs.6703052                                    195 
     2                               rs.1407428                                    571 
                                      rs.6425006                                    327 
                                      rs.17110878                                  203 
     3                               rs.487906                                      511 
                                      rs.9621578                                    299 
                                      rs.5998713                                    169           
  
  2.4.2 PCR Optimization 
 
PCR optimization was performed not only to maximize product yield but also to reduce 
amplification of non-specific products for accurate downstream DNA analysis. Various 
parameters, namely annealing temperature, Magnesium Chloride (MgCl2) concentration 
and primer concentrations of each of the 50 ABCA4 exons and for every multiplex group 
of SNPs in candidate AMD genes were altered during optimization. For each exon an 
optimized singleplex PCR was indicated by a single, bright band at the expected bp size 
while an optimized multiplex PCR had three or four equally bright bands at the expected 
bp size without any non-specific amplification. Further adjustments were introduced for 
samples showing distinct but weak bands. In these cases, DNA concentration was 
increased to 200ng/µl and the number of cycles in the Standard PCR cycling conditions 
was increased to 35. 





        2.4.1.1 Temperature-gradient PCR 
 
Temperature gradient PCR identifies the annealing temperature at which a specific 
primer pair amplifies genomic DNA optimally.  The temperature gradient was chosen to 
cover ±5°C from the calculated primer melting temperature for each exon and SNP 
primer pair. Five identical PCR reactions were set up spanning the temperature range of 
10°C with a no template control (NTC) at the lowest annealing temperature. The NTC is 
added to monitor for contamination in the reaction and was run at the lowest 
temperature where non-specific amplification is generally more pronounced. PCR was 
conducted using 1µl of 100ng/µl DNA in a 25µl reaction volume with the reaction 
mixture (Table 2.5) and the remaining reaction volume was made up using SABAX 
dH2O. All reactions were performed on the MultiGene cycler (Labnet International, Inc. 
Edison, NJ, USA) with standard cycling conditions (Table 2.4) except that the annealing 
temperature was set to span the 10°C interval range specific to that exon or SNP. The 
highest optimal annealing temperature was determined by agarose gel electrophoresis 
(Section 2.2.2). Any exons requiring further optimization were subject to MgCl2 titrations 
or primer titrations.  
 
For each multiplex PCR of SNPs in candidate AMD genes, a single annealing 
temperature was chosen within the overlapping range of potential annealing 
temperatures for each SNP within the group. Each multiplex reaction was then further 
optimized at the chosen annealing temperature with MgCl2 titration experiments. An 
example of a temperature-gradient PCR is shown in Figure 2.3. 
 
    2.4.1.2 Magnesium and pH gradient 
 
Magnesium (Mg2+) serves as an essential co-factor for thermostable DNA polymerase. 
Optimal Mg2+ and pH concentration is essential for Taq DNA Polymerase activity and 







Figure 2.3: Electrophoresis gel photograph showing Temperature-gradient PCR for 
exon 5 of ABCA4. MW: GeneRuler™ 100bp Plus DNA Ladder (Thermo Scientific, 
Waltham, MA, USA), Lane 1 – 6 represents identical PCR reactions differing only with 
respect to the annealing temperature. Lane 1: 55°C, Lane 2: 57.4°C, Lane 3: 58.9°C, 
Lane 4: 61°C, Lane 5: 63.4°C, Lane 6: 65°C, NTC: No-template control. Lane 5 
indicates the optimal annealing temperature, as non-specific products are not amplified.  
      
To determine the optimal Mg2+ and pH combination, an in-house PCR Optimization Kit 
created according to the Roche Optimization Kit manufacturer’s instructions (Roche 
Diagnostics, Basel, Switzerland) was used. This kit contains 16 buffer solutions used to 
generate a MgCl2 and pH gradient (Table 2.7).  Using control DNA, 16 identical 
reactions were prepared with the standard PCR reaction mixture (Table 2.5) differing 
only by buffer solution and run at Standard PCR cycling conditions (Table 2.4). The 
PCR product of each reaction was then subjected to agarose gel electrophoresis 
(Section 2.2.2). The buffer generating a single, distinct band of DNA (or distinct bands in 
the case of a multiplex) at the expected molecular weight was chosen for further 
amplification and sequencing. Each multiplex group of SNPs in candidate AMD genes 
along with ABCA4 exon 31 and 49 were subjected to MgCl2 titration for complete 








Figure 2.4: Electrophoresis gel photograph depicting a Magnesium and pH titration with 
16 buffers from Roche PCR Optimisation kit for exon 49. MW: GeneRuler™ 100bp Plus 
DNA Ladder (Thermo Scientific, Waltham, MA, USA). Lane numbers correspond to 
buffer numbers (Table 2.7), NTC: Non-template control. Buffer 1 was chosen for further 
















Table 2.7: Roche Optimization kit buffers 1-16. Each buffer is numbered to show the 
corresponding MgCl2 and pH concentration.  
 
                      Buffer                    pH                 MgCl2(mM)    
                          1                                                        1 
                          2                                                       1.5 
                          3                                                         2 
                          4                                                       2.5 
                          5                                                         1 
                          6                                                        1.5 
                          7                                                          2 
                          8                                                        2.5 
                          9                                                          1 
                         10                                                        1.5 
                         11                                                          2 
                         12                                                        2.5 
                         13                                                          1 
                         14                                                         1.5 
                         15                                                           2 
                         16                                                         2.5 
 
    2.4.1.3 Primer titration 
 
High primer concentrations inhibit PCR reactions by primer-dimer formation and non-
specific amplification. Primer titration involved four PCR reactions with Standard PCR 
reaction mixture (Table 2.5) differing only by primer concentration, which ranged from 
10pmol to 4pmol in 2pmol intervals, run using Standard PCR cycling conditions (Table 
2.4). The optimal primer concentration was selected as the concentration with the 
brightest, distinct band without any non-specific amplification. Only exon 30 of ABCA4 







Primer concentrations were adjusted to ensure equivalent band intensity of all SNPs in 
candidate AMD genes within a multiplex group. This adjustment was required for SNP 
rs17110878 within multiplex group two where the forward and reverse primer 
concentration was decreased from the standard 10pmol to 3pmol.   
 
  2.4.2 Cohort PCR amplification 
 
Following optimization, each of the 50 ABCA4 exons was amplified for all three test 
samples by PCR. The same optimized conditions for each exon was used for all three 
test samples and confirmed by agarose gel electrophoresis (Section 2.2.2). Similarly, all 
154 AMD samples were amplified by PCR for each optimized multiplex SNP group of 
SNPs in candidate AMD genes. An example of an optimized PCR reaction is shown in 
Figure 2.5 and 2.6. 
 
 
Figure 2.5: Electrophoresis gel photograph showing optimized PCR amplification for 3 
test samples of exon 4 of ABCA4. MW: GeneRuler™ 100bp Plus DNA Ladder (Thermo 
Scientific, Waltham, MA, USA). Lane 1 – 3 contain different samples and NTC the no-







Figure 2.6: Electrophoresis gel photograph showing optimized PCR amplification for  
multiplex group 3 for SNPs in candidate AMD genes. MW: GeneRuler™ 100bp Plus 
DNA Ladder (Thermo Scientific, Waltham, MA, USA). Lane 1 – 5 contain different 
samples and NTC the no-template control.   
 
2.5 Direct cycle sequencing 
 
Following PCR, all three test samples were subjected to direct cycle sequencing of 50 
exons of ABCA4 in both the forward and reverse direction to determine the presence of 
any sequence variants. All exons were successfully sequenced in both directions 
producing satisfactory electropherogram data for variant calling except exon seven 
which only produced interpretable sequencing data from the forward primer. As the 
sequencing data from the forward primer completely covered exon seven and its 
splicing regions, troubleshooting efforts were curtailed for sequencing in the reverse 
direction. Possible factors leading to only one primer producing interpretable 
sequencing data includes poor primer design, a SNP within the reverse primer binding 
site and primer contamination. Both pre- and post-purification was performed prior to 
resolution of the sequence variants on the ABI Prism 3130xl Genetic Analyzer (Applied 
Biosystems, California, USA) automated sequencer.  








  2.5.1 PCR purification reaction  
 
Enzymatic purification was used to purify PCR products before cycle sequencing. In 
order to maintain the ratio of dNTP’s to ddNTP’s for efficient cycle sequencing reactions 
shrimp alkaline phosphatase (SAP) was used to dephosphorylate unincorporated 
dNTP’s. Exonuclease І degrades any unincorporated primers in a three prime to five 
prime direction that could possibly interfere with normal sequencing methods. 
Purification was performed in a 10µl reaction volume with 8.9µl PCR product, 1 unit (U) 
FastAP™ (ThermoFisher Scientific, Waltham, Massachusetts, USA), and 2 U 
Exonuclease І (ThermoFisher Scientific, Waltham, Massachusetts, USA). Purification 
was conducted on the GeneAmp® PCR System 9700 (Applied Biosystems, California, 
USA) and thermal cycling conditions consisted of an initial incubation step at 37°C for 
one hour, followed by an enzymatic inactivation step at 75°C for 15 minutes and a final 
inactivation step at 95°C for five minutes.  
   
  2.5.2 Cycle sequencing reaction 
 
A cycle sequencing reaction is an adapted PCR technique that uses a single primer 
instead of two for linear amplification. Another difference is that it randomly incorporates 
fluorescently labelled ddNTP’s into the three prime end of the amplified template 
fragments which halts the extension process. Sequencing reactions were prepared in a 
20µl mixture of 4µl PCR product, 1x BigDye Termination Sequencing Buffer (Applied 
Biosystems, California, USA), 0.25x BigDye Termination mix (Applied Biosystems, 
California, USA) and either 20 or 40pmol primer (sense or antisense) depending on the 
length of the PCR product. For PCR products longer than 350 bp, 40pmol was used 
whereas 20pmol was sufficient for any products less than 350 bp. The sequencing 
cycling conditions comprised an initial denaturation step at 95°C for five min, followed 
by 30 cycles of 95°C for 30 seconds (sec), 50°C for 15 sec, and 60°C for four min. 
Cycle sequencing reactions were completed on the GeneAmp® PCR System 9700 




  2.5.3 Sequencing purification reaction 
 
Ethanol precipitation was used to purify and concentrate the cycle sequencing products. 
The cycle sequencing products were added to 50µl absolute ethanol (Merck Chemicals, 
Gauteng, SA) and 2µl sodium acetate (3mM, pH5.5). Each sample was mixed and 
incubated overnight at -20°C. All samples were centrifuged at 10 000 revolutions per 
min (rpm) for 10min using the Microcentrifuge 5415D (Eppendorf, New York, USA). The 
supernatant was decanted before adding 50µl of 70% ethanol and a final centrifugation 
at 10 000rpm for 10 min. Again the supernatant was removed and the samples air dried 
for 60min in order to allow any excess ethanol to evaporate, as it would interfere with 
the sequencing.  
   
  2.5.4 Capillary electrophoresis 
 
Each purified sequencing pellet was re-suspended in 10µl SABAX distilled water 
(Adcock Ingram, Johannesburg, SA). After careful pipette mixing, 5µl of the 
resuspended solution was mixed with 8µl of deionized injection solvent, Hi-Di™ 
Formamide (Applied Biosystems, Warrington, UK) in a MicroAmp® Optical 96-well 
Reaction Plate (Applied Biosystems). The reaction plate was loaded into the 
autosampler of the ABI Prism 3130xl Genetic Analyzer (Applied Biosystems) for 
capillary electrophoresis. The following settings were chosen for data capture: the 
analysis module used was 3130BigDyeTerminatorKBv5.2, the dye set was Z-BigDyeV3, 
and the run module was RapidSeq36_POP7_1. Electropherogram data was analysed 
by Sequencing Analysis v5.4 Software for Windows (Applied Biosystems, Copyright 
2009) for viewing and editing. 
 
2.6 Genotyping by SNaPshot 
 
SNaPshot is a modified PCR genotyping method which can cost-effectively investigate 
numerous SNP in various locations in the human genome in a single multiplex reaction. 
All PCR amplicons, each containing a SNP of interest, are pooled within a multiplex 
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reaction with respective internal primers. DNA polymerase facilitates single base 
extension at the three prime end of the internal primer with available fluorescent labelled 
ddNTPs as described in section 2.3.3. Detection of colour peaks by capillary 
electrophoresis corresponding to specific incorporated ddNTPs determines the 
genotype for that sample (Table 2.8).  
 
Table 2.8: Information pertaining to the fluorescently labelled dyes for each ddNTP 




Name of Fluorescent Dye     
Label 
Colour of Analyzed Peak 
Adenine (A) dR6G Green 
Cytosine (C) dTAMRA™ Black 
Guanine (G) dR110 Blue 
Thymine (T) dROX™ Red 
 
  2.6.1 Pre-SNaPshot purification 
 
Prior to the SNaPshot reaction, all amplified PCR products were purified with shrimp 
alkaline phosphatase FastAP™ (ThermoFisher Scientific, Waltham, Massachusetts, 
USA) and Exonuclease І (E. Coli) (New England Biolabs Inc., USA) in order to remove 
unincorporated dNTP’s and primers, respectively.   
Each group multiplex purification reaction for SNPs in candidate AMD genes was 
conducted in a 20µl volume reaction consisting of 5µl PCR product, 1.5 U of FastAP™ 
(ThermoFisher Scientific, Waltham, Massachusetts, USA), 1 U of Exonuclease І (New 
England Biolabs Inc., USA), and SABAX distilled water (Adcock Ingram, Johannesburg, 
SA).   
 
Singleplex purification reactions were conducted with equivalent reaction volumes to 
multiplex purification reactions except that 1U of FastAP™ (ThermoFisher Scientific, 
Waltham, Massachusetts, USA) was used instead of 1.5U. Purification cycling 
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conditions included an incubation step at 37°C for 60 min, followed by enzyme 
inactivation at 75°C for 15 min conducted on the GeneAmp® PCR System 9700 
(Applied Biosystems, California, USA). 
   
  2.6.2 SNaPshot reaction 
 
Following the initial purification step, separate multiplex SNaPshot reactions were 
performed for the three groups of SNPs in candidate AMD genes. For each group of 
SNPs in candidate AMD genes, internal SNaPshot primers were pooled in a ratio of 
1:1:1:1 for group 1 and 1:1:1 for groups two and three, respectively. For every batch of 
multiplex reactions, fresh dilutions of pooled internal primers were used.  
 
Multiplex SNaPshot reactions were conducted in a 10µl reaction volume, consisting of 
5µl purified PCR product, 1µl pooled internal primers and 1µl SNaPshot Multiplex 
Ready Reaction Mix (Applied Biosystems, Warrington, UK). The remaining volume was 
made up using SABAX distilled water (Adcock Ingram, Johannesburg, SA).  
 
Singleplex SNaPshot reactions were conducted with equivalent reaction volumes to 
multiplex SNaPshot reactions except that 1µl purified PCR product was used instead of 
5µl. In order to recognize possible contamination, a negative control was included with 
every multiplex reaction with 1µl distilled water replacing the purified PCR product. 
Cycling conditions for both the multiplex and singleplex SNaPshot reactions were as 
follows: 25 cycles consisting of 10 sec at 96°C, 5 sec at 50°C, and 30 sec at 60°C. All 
experiments were performed on the GeneAmp® PCR System 9700 (Applied 
Biosystems, California, USA). All SNaPshot PCR products were stored at 4°C in dark 
conditions to reduce the loss of fluorescence post PCR.  
 
  2.6.3 Post-SNaPshot purification 
 
Upon conclusion of the SNaPshot reaction, 1 U FastAP™ (ThermoFisher Scientific, 
Waltham, Massachusetts, USA) was added to each reaction to remove unincorporated 
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ddNTP’s. This was followed by an incubation step at 37°C for 60 min and enzyme 
inactivation at 75°C for 15 min conducted on the GeneAmp® PCR System 9700 
(Applied Biosystems, California, USA). 
   
  2.6.4 Capillary electrophoresis and genotype analysis    
 
Subsequent to post-SNaPshot purification, the products were electrophoresed on the 
ABI Prism 3130xl Genetic Analyzer (Applied Biosystems). Firstly, a volume of 9µl of Hi-
Di™ Formamide (Applied Biosystems, Warrington, UK) with 0.2µl GeneScan™ - 
120LIZ™ size standard (Applied Biosystems, Warrington, UK) (Appendix 3) and 1µl of 
purified SNaPshot product was loaded on a MicroAmp® Optical 96-well Reaction Plate 
(Applied Biosystems).  
 
Thereafter, the mixture was denatured for five min at 96°C on the Hybaid Touchdown 
TD-7500 Thermal Cycler (The Scientific Group, Milnerton, SA) and cooled on ice for two 
min. Hi-Di™ Formamide functions as a solvent that re-suspends DNA samples before 
electrokinetic injection while GeneScan™ - 120LIZ™ provides nine single-stranded 
LIZ® dye labeled fragments ranging from 15 to 120 nucleotides which creates a sizing 
curve ideal for SNaPshot genotype analysis. After loading the MicroAmp® Optical 96-
well Reaction Plate within the autosampler, the following settings were chosen for data 
capture: the dye set was E5, and the run module was SNP_36_3V. Output data were 
examined using GeneMapper Software v4.1 (2009) (Applied Biosystems). Separate 
sets of bins and panels were setup for each group within GeneMapper Software v4.1 to 










Table 2.9: Expected and observed genotyping peak data from the multiplex grouping of 
10 SNPs in candidate AMD genes. WT – wild type, Alt – Alternative allele. 
 
SNP                         Nucleotide            Expected            Observed                Allele          
                                  Change               Fragment            Fragment                 peak                                                            
                                                             Length(bp)          Length(bp)            (WT/Alt) 
Group 1 
rs.17110714          g.134151T>C                 28                    36.5/35                   T/C                                 
rs.9621622         c.-163+6142G>A              25                    33/33.5                    C/T           
rs.1555494           c.900+5239A>G             31                    38.5/38                    A/G          
rs.6703052           c.3523-508C>A              41                    47.5/48                    C/A        
Group 2 
rs.1407428         c.268+51430C>A             33                     41/41                     C/A          
rs.6425006          c.269-18380T>C             37                     43/42                     T/C          
rs.17110878        c.4667+544A>G              23                     35/33                     A/G              
Group 3 
rs.487906           c.5460+1537C>G            35                    39/40.5                    G/C  
rs.9621578          c.711+2887A>G             25                    35.5/37                    T/C          
rs.5998713              c.-1975G>T                39                      44/45                     C/A 
 
 
  2.6.5 Genotyping confirmation by cycle sequencing 
 
A selection of samples for each SNP in the candidate AMD genes (representative of 
each individual genotype) were sequenced by direct cycle sequencing to confirm the 
accuracy of the SNaPshot genotyping results.  
 
Sequencing was performed on the singleplex PCR product for the particular SNP and 






2.7 Bioinformatic Analysis 
 
  2.7.1 ABCA4 Sequence alignment and variant identification 
 
All sequencing electropherogram data was uploaded onto BioEdit (Hall 1999) Sequence 
Alignment Editor v7.0.5.3 (Ibis Biosciences, California, USA) for further analysis and 
interpretation. The reference genomic sequence was uploaded from the annotated file 
(Section 2.3.1) in FASTA format, together with both the forward and reverse sequences 
generated from each respective amplicon. For multiple sequence alignment the 
ClustalW (Larkin et al 2007) (Kyoto University, Bioinformatics Center, Japan) application 
in BioEdit (Hall 1999) was used. Only good quality sequence data with tall, well-spaced 
peaks and minimal background interference were evaluated for sequence variations. 
Any sequence variations differing from the reference sequence were then further 
investigated with other bioinformatics tools.   
 
The Human Genome Variation Society (HGVS) (http://www.hgvs.org/mutnomen/) 
contains nomenclature for the description of sequence variants. The most recent 
guidelines and recommendations provided were used to describe sequence variants, 
novel or previously identified, identified among the three test samples.  
 
The Ensembl Project (Flicek et al 2014) (http://www.ensembl.org/) served as the 
genome browser of choice for further variation comparison and annotation. Ensembl 
Release 75 – February 2014 © version provided the comparative sequence in order to 
assess whether a variant was novel or previously identified. Variants identified as novel 
were further compared with the Exome Aggregation Consortium (ExAC) (Lek et al 2015) 
(http://exac.broadinstitute.org/) browser for verification. If previously identified, the SNP 
was further investigated for any gene or regulatory consequences using the SNP 
database, dbSNP (Sherry et al 2001) (http://www.ncbi.nlm.nih.gov/SNP/). Population 
allelic frequencies, especially among African populations, were extracted for every 
sequence variant from the 1000 Genomes Browser 
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(http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) if available (McVean et al 
2012).    
   
   2.7.2 Determination of pathogenicity 
 
    2.7.2.1 Missense variants 
 
Missense mutations are non-synonymous variations where a base change results in a 
different codon that alters the amino acid sequence. To predict whether these mutations 
may be disease causing, the online predictor tool Pathogenic-or-Not-Pipeline (PON-P) 
(Olatubosun et al 2015) (http://bioinf.uta.fi/PON-P/index.shtml) was used.  PON-P 
(Olatubosun et al 2015) incorporates five separate predictor tools to calculate the 
probability that missense mutations alter protein function and lead to disease. The five 
predictor tools are separated into either tolerance or stability predictors. Tolerance 
predictors include Predictor of human Deleterious Single Nucleotide Poly- morphisms 
(PhD-SNP)( version 2.0.6)(http://snps.biofold.org/phd-snp/phd-snp.html), Sorting 
Intolerant From Tolerant (SIFT)(version 4.0.3)( http://sift.jcvi.org/), PolyPhen-2 (version 
2.0.22)(http://genetics.bwh.harvard.edu/pph2/) and Screening For NonAcceptable 
Polymorphisms (SNAP)(version1.0.8)( http://www.ngrl.org.uk/Manchester/ page/snap-
screening-nonacceptable-polymorphisms). The only stability predictor used was I- 
Mutant (version 3.0.6) (http://folding.biofold.org/i-mutant/). Input included both the 
protein FASTA formatted sequence for each exon and the protein variations. PON-P 
(Olatubosun et al 2015)  gives an output value between zero and one, with zero 
considered benign, and one considered pathogenic. A score of 0.5 is seen as uncertain. 
From this value the mutation was classified as either Neutral, Pathogenic or a ‘Variant 
of unknown Significance’ (VOUS). Bootstrapping is used to approximate the standard 
error of the prediction from which the prediction reliability is derived and included in the 
output data.  
 
During our study, the designers of the PON-P (Olatubosun et al 2015)  software 
released a faster and updated version namely, PON-P2 (Niroula et al 2015) 
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(http://structure.bmc.lu.se/PON-P2/) (Lund University, 2013). The identifier submission 
was chosen as input format to input the same four ABCA4 missense variants using the 
Ensembl (Flicek et al 2014) identifier as reference. The output data, in terms of value 
and classification of these missense variations, changed between the two respective 
versions.  
 
    2.7.2.2 Synonymous and intronic variants 
 
Aberrant splicing caused by exonic and intronic point mutations is an important 
mechanism leading to dysfunctional protein formation and genetic disease. In order to 
identify whether any variants lead to splicing defects, Human Splice Finder (HSF) 
Version 2.4.1 (13 October, 2010) (Desmet et al 2009) (http://www.umd.be/HSF/#) was 
used. Input data included both the wild-type and the mutant sequence for each ABCA4 
exon. Before analysis the first and last nucleotide of each exon was manually identified 
to define exon/intron boundaries. The following factors were considered when 
evaluating whether a variant may be pathogenic: 
 
 1. Donor/acceptor splice sites – Two separate matrices were used for prediction of 
potential donor/acceptor sites. Matrices derived from Shapiro and Senapathy (Shapiro 
et al. 1987) were used to derive a consensus value (CV) for each sequence and only 
sequences above a certain threshold value would qualify as potential sites.  Output for 
these matrices was given as donor splice sites or acceptor splice sites. Any mutation 
that resulted in a reduction of 10 % or more in CV for any position, or a reduction of 
seven percent in position +4 for a specific sequence, was deemed to significantly affect 
splicing and hence should be further investigated as it could prove to be pathogenic 
(Desmet et al. 2009). A prediction algorithm modified from the MaxEnt script (Yeo et al. 
2004) was also used to derive sequence predictions for splice site motifs. Output of 
these matrices was given as either 3´ or 5´ motifs.  
 
2. Exonic Splicing Enhancers (ESE) - The spliceosome is guided by various intronic and 
exonic cis-elements to help define exon boundaries. Serine/Arginine-rich (SR) proteins 
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bind to these ESEs to promote exon definition. The binding of SR proteins (SRp40, 
SC35, SF2/ASF, SF2/ASF IgM/BRCA1 and SRp55) to their respective enhancer motifs 
were investigated from previously published algorithms on ESEfinder release 3.0 (2001-
2006, Cold Spring Harbor Laboratory). From the output data only new or disrupted sites 
caused by the mutation were considered significant for further consideration. No definite 
guidelines were provided to confidently assign pathogenicity to any particular disrupted 
or newly created SR site but studies have shown that disruption in even one motif can 
result in disease, as shown by Cartegni et al. (2002) in spinal muscular atrophy. 
Therefore, in this study we ascribe significant weight to any variation that disrupts an 
ESE as possibly mutational.   
 
3. Branching points - The branching point (BP) motif acts as an obligatory signal for pre-
mRNA splicing. Only BP’s within 100 nucleotides from the exon were considered for 
further processing. The threshold value of 67 was calculated using the consensus 
sequence YNYCRAY together with certain exclusion algorithms and a position weight 
matrix. Noteworthy variations reduced the threshold value below 67 and therefore 
resulted in a disrupted BP (Desmet et al. 2009).    
 
2.8 Screening for possible pathogenic ABCA4 variants in the    
      STGD cohort 
 
All variants tracking with the three common haplotypes indicated by PHASE (Stephens 
et al. 2001) analysis were pooled together to facilitate the determination of a possible 
novel mutation (Table 2.10). Haplotype four contained four synonymous changes, of 
which three were determined to be pathogenic by HSF along with two intronic variants 
namely c.5835+122T>G and c.5836 -11 G>A. Haplotype 12 contained three pathogenic 
variants as predicted by HSF - the exception being the c.2589 -39 T>C variant. 
Haplotype 29 had the only missense variants observed among all the haplotypes, 
although both were deemed benign after re-analysis by PON-P2 (Niroula et al 2015). 
The variant, c.3329 -34 A>G was deemed pathogenic by HSF, meaning all haplotypes 
contained at least one predicted pathogenic variation. Since no obvious mutational 
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changes were sequenced i.e. nonsense variants or intronic insertions/deletions within 
each haplotype, it was decided to rather screen the haplotype cohort for the three most 
probable pathogenic variants among all the variants found. The rationale for this 
decision is further discussed within the Discussion section.  
 
Table 2.10: List of all variants occurring within each of the 3 common haplotypes.  
 
     Haplotype 4                            Haplotype 12                           Haplotype 29  
    c.3329 -58 C>T                       c.2589 -38 G>C                        c.3329 -34 A>G                       
   c.5461-44 dupG                       c.2589 -39 T>C                   c.3602 T>G p.L1201R 
c.5682 G>C p.L1894L                 c.6282 +7 G>A                    c.6764 G>T p.S2255I 
c.5814 A>G p.L1938L             c.6249 C>T p.I2083I                     c.5715-25A>C 
    c.5835+122T>G 
c.5844 A>G p.P1948P 
  c.6069 T>C p.I2023I 
     c.5836 -11 G>A 
 
Various factors were taken into account when choosing the most likely pathogenic 
variants for further genotyping. These factors include: 
1. Clinical significance: any known association with STGD or previous determined 
pathogenicity by segregation analysis or functional studies. 
2. Population frequencies: any mutant type alleles present in more than 10% of the 
normal African population as extracted from the Ensembl Genome Browser 
(Flicek et al 2014) were regarded as improbable to be pathogenic.  
3. Splice site location: Variants situated within 10-15 bases of the intron/exon 
boundary especially on the five prime end were prioritized above variants 
situated far from the splice region for each exon. 
4. PON-P results: The predicted class as indicated by the re-analysis by PON-P2 
carried much significance in regard to pathogenicity determination.  
5. HSF findings: Only variants with pathogenic changes as indicated within HSF 
parameters were considered specifically if changes involved branching points 




The two missense variants which were found to be pathogenic, L1202R and V643M, 
according to PON-P (Olatubosun et al 2015) (the initial version used) were obvious 
choices. The third variant chosen was the synonymous variant, c.3831 G>A p.T1277T, 
in exon 26. HSF predicted it to alter exon structure and expression by forming a new 
branching and acceptor splice site, breaking existing five prime and three prime motifs 
and breaking a SF2/ASF enhancer site while forming two new SRp40 sites. Its position 
within the first 15 bases of the exon is critical to splicing of various transcripts and this 
supports its mutational effects as indicated by HSF. Reinforcing its pathogenic 
possibility is its relatively low minor allele frequency of three percent in the general 
population.   
 
  2.8.1 Screening for L1201R by Restriction Fragment Length Polymorphism   
           analysis 
 
Restriction Fragment Length Polymorphism (RFLP) analysis is a genotyping technique 
based on the ability of restriction endonucleases (RE) to cleave DNA at specific 
recognition sites, usually four to six base pairs long. SNP’s alter enzyme recognition 
sites and result in different DNA fragment lengths when incubated with RE’s.  To 
determine the suitability of RFLP as a genotyping technique, all three potentially 
pathogenic ABCA4 variants were analyzed with Webcutter version 2.0 (Maarek et al 
1997) (http://rna.lundberg.gu.se/cutter2). The wild type DNA sequence was entered as 
input data and analyzed with a linear sequence method. Output display included a map 
of all restriction sites caused by all RE in the database. This process was repeated for 
the mutant DNA sequence containing the variant change and then compared to the wild 
type sequence. Disrupted enzyme recognition sites were further investigated to 
determine the number of cleavage sites within the amplified sequence for the specific 
RE and the resulting fragment lengths.  
 
After analysis of all three haplotype-associated variants using Webcutter version 2.0 
(Maarek et al 1997), only the L1202R variant was found to be detectable by RFLP. Msp 
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І was shown to cleave once, at a site 201bp into the 287 bp amplicon on the sequence 
containing the L1201R variant, but not on the wild type sequence. The single cut 
resulted in sufficient fragment size difference to be viewed on a two percent w/v 
agarose gel (Figure 2.7) (Table 2.11). The other possible pathogenic mutations, V643M 
and T1277T, were run on Webcutter version 2.0 (Maarek et al 1997) to assess whether 
they could be detected by RFLP.  The V643M mutation caused an alteration to two RE 
recognition sites in the amplicon sequence in comparison to the wild type sequence. 
Both these REs cleave the sequence at three other sites within the amplicon, thereby 
creating numerous fragments indistinguishable by agarose gel electrophoresis. The 
T1277T mutation created no changes in RE recognition sites.   
 
Table 2.11: Information regarding the restriction endonuclease Msp І used to detect the 
presence of the L1201R variant. 
      
PCR product size                       Restriction                               Recognition site 
                                                 Endonuclease 
        287 bp                                     Msp І                                     5´-agtcc*gggat-3´ 
                                                                                                      3´-tcagg*cccta-5´                                            
                        
                           Wild Type           Heterozygous              Homozygous 
287bp                                                 
201bp                                                                                          
 
86bp                                                                                            
 
Figure 2.7: Illustration of expected DNA fragments for the restriction endonuclease 
digest screening of the L1201R mutation using Msp І. Wild type sequence without the 
L1201R mutation and both Heterozygous and Homozygous mutation sequences are 
shown.  
 
All 14 of the haplotype samples were screened for the L1201R mutation by RFLP. Msp І 
(New England Biolabs, Ipswich, MA, USA) restriction endonuclease was obtained from 
the library of restriction enzymes stored within UCT’s Division of Human Genetics at -
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20°C. Firstly, a reaction mixture was prepared (Table 2.5). Aliquots of 8µl from the 
vortexed mixture were added into separate tubes containing 12µl PCR products from to 
equal a final reaction volume of 20µl. Individual tubes were incubated overnight at 37°C 
on a Bio TDB-100 (BioSan, Latvia) dry block thermostat before an additional three units 
Msp І enzyme and dH2O was included for another 90 minutes.  
 
Table 2.12: Reaction mixture used for RFLP analysis 
 
Reagents                                                                      Final Concentration 
Msp І                                                                                    5 units (U) 
NEB Buffer (New England Biolabs, Ipswich, MA, USA)            1 x 
SABAX distilled H2O                                                                5.75µl 
 
All haplotype samples were then subjected to agarose gel electrophoresis as per 
Standard Electrophoresis conditions except that the full 20µl post-digest reaction 
volume was used. L1201R variant positive and negative controls were added with the 
haplotype samples for comparison and to confirm success of the restriction digest.   
 
  2.8.2 Detection of T1277T and V643M mutation by direct cycle sequencing 
 
Cycle sequencing was performed to screen the haplotype samples for the remaining 
mutations as they did not result in an altered RE recognition site. The mutation T1277T 
is located 18 bp into exon 26 and V643M 167 bp into exon 13. In order to screen for the 
presence of the mutations in all haplotype samples both exon 13 and 26 were 
sequenced by direct cycle sequencing. Firstly, both exons were amplified by PCR as 
per previously determined optimized conditions and confirmed by agarose gel 
electrophoresis. Amplified PCR products of all haplotype samples for both exons were 
then enzymatically purified and sequenced (Section 2.5) on the ABI Prism 3130xl 
Genetic Analyzer (Applied Biosystems). All electropherogram data were analyzed and 




Chapter 3: Results 
 
3.1 Patient recruitment 
   
3.1.1 Interrogation of the UCT Retinal Registry Database for STGD samples 
 
The UCT Retinal Registry contains 234 STGD patients (212 families) divided ethnically 
into 178 Caucasian, 36 African, seven Mixed Ancestry (MA) and six Indian families, 
respectively. Of the 178 Caucasian probands, 104 (58.4 %) had their disease-causing 
mutations identified, compared to two (28.6 %) MA and two (33.3 %) Indian probands 
(Unpublished data). Only four of the 36 (11 %) African STGD probands in the UCT 
Retinal Registry that had been tested with the ABCR400 microarray had both  mutated 
alleles of ABCA4 identified, 11 (31%) had one mutated allele identified and 21 (58%) 
had no mutations identified (Unpublished data). 
 
  3.1.2 PHASE Haplotype analysis for STGD sample selection 
 
Haplotype analysis of all 32 unrelated African STGD patients in which only one or no 
mutations were identified, showed a total of 35 different haplotypes. Haplotypes are 
assigned random numbers and three of these haplotypes, numbered 29, four and 12 
respectively, occurred most frequently within the cohort.  
 
Of these 32 African STGD patients, 17 carry at least one of the three common 
haplotypes determined by PHASE analysis (Stephens et al. 2001). Of these 17, five 
carry a combination of two of the most frequently observed haplotypes. Out of these 
five, three test samples were chosen to represent each unique combination of the 





Table 3.1: Test samples representative of each unique combination of the three 
common haplotypes chosen for DNA sequencing to find novel ABCA4 mutations. 
Haplotype numbers are those allocated by PHASE. 
 
                          Test Sample                    Haplotypes  
                          RPM 1004.1                          (12,29) 
                          RPM 1075.1                           (4,12) 
                          RPS 1230.1                            (4,29)   
 
 
3.2 Sequence Analysis 
 
All 50 ABCA4 exons were successfully sequenced in both the forward and reverse 
direction except for exon seven which was only sequenced in the forward direction, in 
each of the three test samples. The electropherogram data produced was of sufficient 
quality for alignment and variant interpretation for all exons and splicing regions in the 
three test samples.  Variations were accepted as genuine if present on both the forward 
and reverse strand for the specific exon. Heterozygous SNPs were called if a single 
peak position contained two overlapping peaks of fluorescence (Figure 3.1). 
 
                      
 
Figure 3.1: An electropherogram representing a segment of sequencing from the 
forward strand of exon 44 for test sample RPS 1230.1. The actual sequence called is 
indicated above the peaks with each colour representing a different nucleotide. The R 
peak at position 65 (indicated with an arrow) indicates the presence of the heterozygous 
SNP c.6006 -16G>A. An R peak is called when an A and a G nucleotide occur at the 




Homozygous SNP’s were called using the ClustalW (Larkin et al 2007) alignment 
sequence in Bioedit (Hall 1999) by comparing the annotated and the sample sequence 
(Figure 3.2).  
 
                           
 
Figure 3.2: Multiple sequence alignment showing a homozygous change, c.6285 T>C, 
p.D2095D, in exon 46 for RPM 1075.1. The top sequence is uploaded from the 
annotated file and serves as the reference sequence for comparison to determine 
whether a variant is present. The second and third row of sequence corresponds to the 
forward and reverse sequence from the sample. The highlighted base at position 65 
indicates where a C base is called instead of a T base indicating a homozygous change 
for that specific locus.   
 
Heterozygous deletions and insertions cause multiple heterozygous peaks, as they 




Figure 3.3: An electropherogram representing a segment of sequencing from the 
forward strand of exon 10 for test sample RPS 1230.1 showing a heterozygous insertion 
c.1356+5_1356+6 insG. The actual sequence called is indicated above the peaks with 
each colour representing a different nucleotide. The insertion is identified by normal 
sequence followed by multiple heterozygous peaks as the one allele is shifted by the 




A total of 39 unique sequence variants were identified among the three test samples 
(Table 3.2). Of these 39, only three were considered novel as they have not been 
previously documented (according to our knowledge). Novelty was verified through 
comparison with the ExAc Browser (Lek et al 2015). Two of these novel variants, c.6148 
-9 C>T and c.6148 -11 C>T, occur in all three test samples within the splicing region of 
exon 45 (Figure 3.4). The third novel variant, c.6480 +36 G>A, was found in the intronic 
region of exon 48 and was present only in RPS 1230.1 (Figure 3.5).  
 
Appropriate concerns were raised whether these variants were to be considered real 
due to the noisy background on the electropherogram (Figure 3.4) apparent as multiple 
small and indeterminate peaks. Although plagued by similar background noise, the 
forward strand did show the same base call for both variants. The full list of sequence 
variants identified is shown in Table 3.3.  
 
                                            
 
Figure 3.4: An electropherogram representing a segment of sequencing from the 
reverse strand of exon 45 for RPM 1004.1 showing two novel variants c.6148 -9 C>T 
and c.6148 -11 C>T that were identified in all three test samples. The actual sequence 
called is indicated above the peaks with each colour representing a different nucleotide. 
The base call Y at position 43 and 45 indicates a Thymine base simultaneously 













Table 3.2: Total number of variations found for each of the three test samples after 
sequencing of all 50 exons of ABCA4.   
 
                             RPM 1004.1  RPM 1075.1  RPS 1230.1    All 3 TS* 
Intronic                      13                 14                    14                 23 
Missense                     2                  1                      3                  4 
Insertion                      1                  2                      2                  2 
Deletion                       1                  1                      1                  1 
Synonymous               3                  7                      8                  9   
Novel                            2                  2                      3                  3 
Total                            20                25                    28                 39              
 
* The heading ‘All 3 TS’ indicates the total number of unique variants found between the 
three test samples for that specific type of variant. 
 
Table 3.3: List of all unique variants found among the three test samples after 
sequencing all 50 exons of ABCA4. Test Sample indicates in which sample(s) the 
specific variant occurs. Test Sample 1 – RPM 1004.1, Test Sample 2 – RPM 1075.1, 
Test Sample 3 – RPS 1230.1. A total number of 39 unique variants were found.   
 
Variant Type    Exon               Variant                        Test Sample 
Synonymous        2           c.141 A>G p.P47P                    1,2,3 
Intronic                 3             c.302 + 26 A>G                       1,2,3 
Missense              6          c.677 G>T p.R226L                       3 
Intronic                 7             c.858 + 14 T>C                           1 
Intronic                 9             c.1239+66 G>A                           1 
Insertion              10       c.1356+5_1356+6 insG                1,2,3 
Intronic                10            c.1240 -14 C>T                        1,2,3 
Intronic                10              c.1356+6 G>C                           2 
Missense             13         c.1927 G<A p.V643M                     2 
Intronic                18             c.2589 -38 G<C                        1,2  
Intronic                18             c.2589 -39 G<C                        1,2 
Intronic                21             c.2919 -14 T<A                           2 
Deletion               23             c.3329 -112delT                      1,2,3 
Missense             24         c.3602 T<G p.L1201R                  1,3 
Intronic                23             c.3329 -34 A>G                         1,3 
Intronic                24               c.3523-85C>T                          2,3 
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Synonymous       26         c.3831 G>A p.T1277T                     3 
Intronic                33             c.4773 + 48 C>T                       1,2,3 
Intronic                34              c.4774 +42 A>G                         3 
Insertion              39        c.5461-51_5461-50insG                  2,3 
Synonymous       40          c.5682 G>C p.L1894L                   2,3 
Synonymous       41          c.5814 A>G p.L1938L                   2,3 
Intronic                41                c.5715-25A>C                         2,3 
Intronic                41               c.5835+122T>G                       2,3 
Intronic                42               c.5836 -11 G>A                        2,3 
Synonymous       42           c.5844 A>G p.P1948P                  2,3 
Synonymous       44            c.6069 T>C p.I2023I                    2,3 
Intronic                44               c.6006 -16G>A                           3 
Novel Intronic      45                c.6148 -9 C>T                        1,2,3 
Novel Intronic      45             c.6148 -11 C>T                         1,2,3 
Synonymous       45           c.6249 C>T p.I2083I                     1,2 
Intronic                45               c.6282 +7 G>A                          1,2 
Synonymous       46          c.6285 T>C p.D2095D                  1,2,3 
Novel Intronic      48               c.6480 +36 G>A                          3 
Missense             49           c.6764 G>T p.S2255I                   1,3 
Synonymous       49           c.6732 G>A p.V2244V                    3 
Intronic                49                c.6730 -3T>C                             1 
Intronic                49               c.6816 +28 G>C                          1 
Intronic                50                c.6817-85 C>T                           3 
 
3.3 Determination of pathogenicity of ABCA4 variants 
   
  3.3.1 Missense variants 
 
PON-P (Olatubosun et al 2015) was used to evaluate the pathogenicity of the four 
missense variants found in the three test samples (Table 3.4). As described previously 
(Section 2.7.2.1) a ‘probability of pathogenicity score’ of ‘0’ (zero) categorizes the 
variant as benign and ‘1’ (one) as pathogenic. Two of these variants, V643M and 
L1201R, were classified as pathogenic. The mutation, S2255I, was deemed benign and 
R226L considered a VOUS.  
 
As the more reliable, accurate and updated version of PON-P (Olatubosun et al 2015) 
became available during the course of this study all four missense variants were re-






                          
 
Figure 3.5: An electropherogram representing a segment of sequencing from the 
forward strand of exon 48 for test sample RPS 1230.1 showing the novel variant c.6480 
+36 G>A. The actual sequence called is indicated above the peaks with each colour 
representing a different nucleotide. The R base called at position 320 occurs when both 
an Adenine and a Guanine base have equal fluorescence for that locus.  
 
Table 3.4: List of all four missense variants identified in ABCA4 of the three test 
samples with the respective PON-P results. 
 
Exon             Mutation             Predicted       Probability of        Test 
                                                     class           pathogenicity      sample   
    6      c.677 G>T, p.R226L     Unknown               0.17                     3 
   13     c.1928 G>A, p.V643M  Pathogenic            0.88                     2 
   24     c.3602 T>G, p.L1201R Pathogenic            0.88                   1, 3 
   49      c.6764 G>T, p.S2255I   Neutral                 0.11                   1, 3 
 
Table 3.5: List of all four missense variants identified in ABCA4 of the three test 
samples with the respective PON-P2 results. 
 
Exon              Mutation           Predicted   Probability of           Test 
                                                    class        pathogenicity         sample   
    6      c.677 G>T, p.R226L    Unknown            0.47                       3 
   13    c.1928 G>A, p.V643M  Pathogenic         0.95                       2 
   24    c.3602 T>G, p.L1201R  Unknown           0.61                     1, 3 




The probability of pathogenicity values changed for each variant but only mutation 
L1201R dropped significantly enough to alter the predicted class from pathogenic to 
unknown. The allelic frequencies of each missense variant were extracted from the 
1000 Genomes (McVean et al 2012) African population data comprising of the ‘Yoruba 
in Nigeria’, ‘Luhya in Kenya’ and ‘Americans of African descent’; which totalled 245 
samples. The V643M mutation showed a C:T allelic ratio of 99:1. The L1201R and 
S2255I mutations showed a A:C allelic ratio of 91:9 and 52:48, respectively. The R226L 
mutation had no 1000 Genomes (McVean et al 2012) data available for these African 
populations. After considering both software pathogenicity predictions and population 
frequencies for each of the four missense mutations, only the V643M mutation was 
regarded pathogenic.   
  
  3.3.2 Synonymous and intronic variants 
 
Pathogenicity prediction was done in silico for each synonymous and intronic variant 
through the Human Splice Finder Version 2.4.1 (Desmet et al 2009) (13 October, 2010) 
(http://www.umd.be/HSF/#). Results were restricted to variants with significant changes 
occurring in donor/acceptor splice sites, or affecting exonic splicing enhancers and 
branching points as these are the only parameters that provided pathogenicity 
thresholds (Table 3.6) (Desmet et al. 2009).These thresholds include a reduction of 
10% in CV value in any position or seven percent in position four for donor/acceptor 
splice sites, any disruption of ESE sites and broken branching points caused by a 
threshold value under 67 (Section 2.7.2.2).  
 
Table 3.6:  List of variants with pathogenic changes in donor/acceptor splice sites, 
exonic splicing enhancers or branching points as predicted by Human Splice Finder. 
D/A – Donor/Acceptor, ESE – Exonic Splicing Enhancers.  
    
Variant                        D/A splice site       ESE             Branching points  
c.141 A>G p.P47P                                    SRp40                AACCCAC 
c.302+26 A>G                 Acceptor  
                                         3' motif  
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                                         5' motif 
c.1239+66 G>A               2 Donor           2 SRp55 
c.1356+5_1356+6insG   5´ motif 
c.1240-14 C>T                3´ motif 
c.1356+6 G>C                Acceptor 
                                        5´ motif 
c.2589 -38 G>C                                  SRp40, SC35 
c.2919 -14 T>A               3´ motif 
c.3329 -34 A>G              Acceptor 
                                        Donor 
c.3523-85C>T                                  SF2/ASF (IgM-BRCA1)  
                                                                 SF2/ASF 
c.3831 G>A p.T1277T   3´ motif               SF2/ASF 
                                       5´ motif 
c.4773 + 48 C>T                                        SC35 
c.5682 G>C p.L1894L   3´ motif                 SC35 
c.5814 A>G p.L1938L   3´ motif                                           ATCTTAA 
c.5835+122T>G            3´ motif 
                                        Donor 
c.5836 -11 G>A                                     SC35, SRp55 
c.5844 A>G p.P1948P  Acceptor 
                                      5´ motif                   
c.6249 C>T p.I2083I                     SF2/ASF (IgM-BRCA1)   ATCGCAC 
c.6282 +7 G>A                                     SC35, SRp40 
c.6480 +36 G>A           Acceptor                                                 
c.6816 +28 G>C           Acceptor                 SC35 
c.6817 -85 C>T                                     SC35,SRp40 
 
HSF predicted that 22 different variations resulted in possible pathogenic changes due 
to interference with splicing sites. This equates to a remarkable 59 % of all sequence 
variants found being deemed pathogenic, according to HSF.  These results did not 
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include newly formed branching or SR protein binding sites as these were not deemed 
pathogenic by HSF. Due to the complexity of in silico mutational analysis especially in 
splicing regions, it was difficult to choose a clear variant for further mutational screening 
within the haplotype groups. Factors such as distance from the intron/exon boundary 
and allelic frequencies within African populations were considered when deciding upon 
candidates for mutational screening. Test sample one had nine predicted possible 
pathogenic changes according to HSF while test samples two and three had 16 and 12 
changes, respectively. This overestimation of pathogenicity and inability to rank the 
severity between different pathogenic variants caused the screening for these variants 
in the extended cohort of samples with haplotypes to be abandoned.  
 
3.4 Screening for possible pathogenic ABCA4 variants in an extended 
cohort 
  
  3.4.1 Detection of L1201R mutation by RE Msp І 
 
All 14 haplotype samples were subjected to gel electrophoresis after overnight 
incubation with RE Msp І in order to genotype for the L1201R mutation. Two haplotype 
samples namely RPM 398.1 and RPM 1168.1, showed banding patterns indicative of a 
heterozygous L1201R mutation (Figure 3.6). All other samples showed a wild type 







Figure 3.6: Electrophoresis gel image showing a restriction enzyme digest of seven 
haplotype samples with Msp І for mutation L1201R. MW: GeneRuler™ 100bp Plus DNA 
Ladder (Thermo Scientific, Waltham, MA, USA). Lane 1 – 7: Haplotype samples. NC: 
negative control. PC: positive control. Lane 3 (RPM 398.1) and 5 (RPM 1168.1) showed 
banding patterns consistent with a heterozygous L1201R mutation.   
   
  3.4.2 Detection of the V643M and T1277T mutation by direct cycle sequencing 
 
All 14 haplotype samples were sequenced for the V643M and T1277T mutations. Both 
exons 13 and 26 showed sequence data of satisfactory quality for mutation screening. 
None of the 14 samples were found to be positive for the V643M mutation, while only 
one sample (RPM 960.2JIM), was found to be heterozygous for the T1277T mutation.  
 
In summary, of the 36 African STGD cohort, only four patients (i.e. 11%) had a 
complete molecular diagnosis, i.e. two mutations, and 11 patients had only one 
mutation after microarray screening. After exon sequencing of ABCA4 of three samples 








definitive novel pathogenic mutations were found. All samples within the indigenous 
African STGD cohort containing any of the three common haplotypes were screened for 
the three most probable pathogenic variants found after sequencing and in silico 
pathogenicity prediction. One pathogenic mutation, L1201R, was re-classified as an 
‘Variant of Unknown Significance’ according to the updated version of software 
prediction program, PON-P2 (Niroula et al 2015). In light of the above screening results 
and new pathogenic status of the L1201R mutation, only two patients (i.e. six percent) 
of the 36 African STGD cohort remain with two identified heterozygous mutations, ten 
patients have one heterozygous mutation and 24 patients still have no mutations 
identified.  
 
3.5 Genotyping of SNPs in candidate AMD genes by SNaPshot 
 
As explained in Section 2.1.3, the next part of the investigation involved identifying 
protective or susceptibility loci for AMD based on significant allelic frequency differences 
in genes previously associated with AMD. 
 
Screening for the 10 SNPs was conducted on a cohort of 154 individuals diagnosed 
with AMD. Of these individuals, 127 were fully genotyped for all ten SNPs. Failure to 
genotype the full complement of SNPs for the remaining samples was most likely due to 
DNA degradation, and impurities. The 127 AMD individuals were further divided into 
Caucasians, African and Mixed Ancestry for further data analysis. Nine of the ten SNPs 
were incorporated into three different multiplex groups consisting of four (Figure 3.7), 
three (Figure 3.9) and two (Figure 3.11) SNPs respectively (Table 2.6), while 
genotyping for rs487906 SNP was performed using a ‘singleplex’ SNaPshot reaction 








Table 3.7 Allele frequencies within AMD cohort for each SNP in candidate AMD genes. 




Caucasian Mixed Ancestry Africans 
Cases Controls Cases Controls Cases Controls 
rs9621622 .995/.005 .999/.001 1.00/.000 .880/.120 1.00/.000 .607/.393 
rs9621578 .980/.020 .995/.005 .973/.027 .780/.220 .833/.167 .714/.286 
rs5998713 .930/.070 .950/.050 .917/.083 .570/.430 .611/.389 .486/.514 
rs1555494 .970/.030 .999/.001 .780/.220 .740/.260 .444/.556 .243/.757 
rs1407428 1.00/.000 .995/.005 .917/.083 .820/.180 .667/.333 .614/.386 
rs6425006 1.00/.000 .995/.005 .917/.083 .730/.270 .778/.222 .679/.321 
rs17110714 .985/.015 .965/.035 .917/.083 .630/.370 .833/.167 .514/.485 
rs6703052 .920/.080 .955/.005 .840/.160 .650/.350 .556/.444 .471/.529 






Figure 3.7: A SNaPshot reaction electropherogram for a sample that shows the wild 
type allele for all four SNPs within Multiplex group one namely, rs1555494, rs6703052, 
rs17110714 and rs9621622. GeneScan™ 120LIZ™ Size standard is shown at 35bp 
and 50bp. Black peak: cytosine dideoxynucleotide. Red peak: Thymine 
dideoxynucleotide. Blue peak: Guanine dideoxynucleotide. Green peak: Adenine 
dideoxynucleotide. 
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Figure 3.8: A SNaPshot reaction electropherogram of Multiplex group one for a sample 
that is homozygous for the alternative allele for both SNP rs1555494 and rs6703052, 
heterozygous for the rs17110714 SNP and wild type for the rs9621622 SNP. Size 






Figure 3.9: A SNaPshot reaction electropherogram for a sample that shows the wild 
type allele for all three SNPs within Multiplex group two namely, rs17110878, rs6425006 
and rs1407428.  Size standard and colours of peaks as described in Figure 3.7 
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Figure 3.10: A SNaPshot reaction electropherogram of Multiplex group two for a 
sample that is heterozygous for the SNP rs17110878 and rs6425006 and homozygous 
for the alternative allele for SNP rs1407428.  Size standard and colours of peaks as 






Figure 3.11: A SNaPshot reaction electropherogram for a sample that shows the wild 
type allele for two SNPs within Multiplex group three namely rs5998713 and rs9621578.  
Size standard and colours of peaks as described in Figure 3.7 
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Figure 3.12: A SNaPshot reaction electropherogram of Multiplex group three for a 
sample that is heterozygous for the rs5998713 SNP and wild type for the rs9621578 







Figure 3.13: A SNaPshot reaction electropherogram for a sample that shows the wild 
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  3.5.1 Identification of protective SNP alleles in candidate AMD genes   
 
For this, the second part of the research, and to determine whether SNPs in the 
candidate AMD genes were protective against AMD in the African population, there had 
to be a significant difference (decrease) in the minor allele frequency (MAF) of the 
indigenous African AMD cohort versus the African controls. The online software 
analysis tool, SHEsis (Yong 2005) (http://analysis.bio-x.cn/myAnalysis.php), was used 
for analysis.  
 
Single site analysis was used and input data for both cases and controls were entered 
in the required format. SNPs that showed a decreased MAF in the AMD cases 
compared to controls in Africans were considered as possibly protective SNPs. The 
Pearson’s p value (< 5 x 10-2) within the output data was used to determine significance 
of these possibly protective SNPs, instead of the Fischer’s p value, due to sample size.    
 
  3.5.2 Detection of rs9621622 in TIMP3  
 
The heterozygous rs9621622 SNP in TIMP3 was detected only once in 254 samples 
(Table 3.7) and verified by cycle sequencing (Figure 3.14). The difference in minor allele 
frequency between the Caucasian AMD and Caucasian Control cohort respectively 
(Table 3.7), is not significant with a p value of 5.56 x 10-1. The difference in minor allele 
frequency between the African AMD and African Control cohort respectively (Table 3.7), 
is significant with a p value of 9.95 x 10-4. The wild type allele i.e. the absence of the 
rs9621622 SNP, in a sample was represented on the electropherogram by a black 
peak, indicative of a C allele (Figure 3.7) (Figure 3.8). The presence of a heterozygous 
rs9621622 SNP in a sample was represented on the electropherogram by a black and 
red peak, indicative of a C and T allele, respectively. A homozygous rs9621622 SNP 






Figure 3.14: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs9621622 SNP within TIMP3. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The R 
base called at position 107 (indicated with an arrow) represents the heterozygous 
rs9621622 SNP which occurs when both an A and a G base have equal fluorescence 
for that locus.  
   
3.5.3 Detection of rs9621578 in TIMP3 
 
The heterozygous rs9621578 SNP was detected in eight out of 254 samples (Table 3.7) 
and verified by cycle sequencing (Figure 3.15). The difference in minor allele frequency 
between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7), is 
not significant with a p value of 1.84 x 10-1. The difference in minor allele frequency 
between the African AMD and African Control cohort respectively (Table 3.7), is not 
significant with a p value of 2.85 x 10-1. The wild type allele i.e. the absence of the 
rs9621578 SNP, in a sample was represented on the electropherogram by a red peak, 
indicative of a T allele (Figure 3.11) (Figure 3.12). The presence of a heterozygous 
rs9621578 SNP in a sample was represented on the electropherogram by a red and 
black peak, indicative of a T and C allele, respectively. A homozygous rs9621578 SNP 









Figure 3.15 An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs9621578 SNP within TIMP3. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The R 
base called at position 149 (indicated with an arrow) represents the heterozygous 
rs9621578 SNP which occurs when both an A and a G base have equal fluorescence 
for that locus. 
 
  3.5.4 Detection of rs5998713 in TIMP3 
 
The heterozygous rs5998713 SNP was detected in 22 out of 254 samples and in the 
homozygous state once (Table 3.7). Each separate genotype was confirmed by cycle 
sequencing (Figure 3.16) (Figure 3.17). The difference in minor allele frequency 
between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7), is 
not significant with a p value of 4.29 x 10-1. The difference in minor allele frequency 
between the African AMD and African Control cohort respectively (Table 3.7), is not 
significant with a p value of 3.16 x 10-1. The wild type allele i.e. the absence of the 
rs5998713 SNP, in a sample was represented on the electropherogram by a black 
peak, indicative of a C allele (Figure 3.11). The presence of a heterozygous rs5998713 
SNP in a sample was represented on the electropherogram by a black and green peak, 
indicative of a C and an A allele, respectively (Figure 3.12).  A homozygous rs5998713 






Figure 3.16 An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs5998713 SNP within TIMP3. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The K 
base called at position 70 (indicated with an arrow) represents the heterozygous 
rs5998713 SNP which occurs when both an A and a C base have equal fluorescence 







Figure 3.17 An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs5998713 SNP within TIMP3. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The T 
base called at position 73 (indicated with an arrow) represents the heterozygous 
rs5998713 SNP. 
 
    3.5.5 Detection of rs1555494 in HMCN1   
 
The heterozygous rs1555494 SNP was detected in 16 out of 254 samples and in the 
homozygous state four times (Table 3.7). Each separate genotype was verified by cycle 
sequencing (Figure 3.18) (Figure 3.19). The difference in minor allele frequency 
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between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7), is 
not significant with a p value of 1.62 x 10-1. The difference in minor allele frequency 
between the African AMD and African Control cohort respectively (Table 3.7), 
approaches significance with a p value of 6.84 x 10-2. The wild type allele i.e. the 
absence of the rs1555494 SNP, in a sample was represented on the electropherogram 
by a green peak, indicative of an A allele (Figure 3.7). The presence of heterozygous 
rs1555494 SNP in a sample was represented on the electropherogram by a green and 
blue peak, indicative of an A and G allele, respectively. A homozygous rs1555494 SNP 




Figure 3.18: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs1555494 SNP within HMCN1. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The G 












Figure 3.19: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs1555494 SNP within HMCN1. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The R 
base called at position 59 (indicated with an arrow) represents the heterozygous 
rs1555494 SNP which occurs when both an A and a G base have equal fluorescence 
for that locus.  
  
   
  3.5.6 Detection of rs1407428 in HMNC1  
 
The heterozygous rs1407428 SNP was detected in three out of 254 samples and in the 
homozygous state three times (Table 3.7). Each separate genotype was confirmed by 
cycle sequencing (Figure 3.20) (Figure 3.21).The difference in minor allele frequency 
between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7) is 
not significant with a p value of 3.12 x 10-1. The difference in minor allele frequency 
between the African AMD and African Control cohort respectively (Table 3.7), is not 
significant with a p value of 6.66 x 10-1. The wild type allele i.e. the absence of the 
rs1407428 SNP, in a sample was represented on the electropherogram by a black 
peak, indicative of a C allele (Figure 3.9). The presence of a heterozygous rs1407428 
SNP in a sample was represented on the electropherogram by a black and green peak, 
indicative of a C and an A allele, respectively. A homozygous rs1407428 SNP was 






Figure 3.20 An electropherogram representing a segment of sequencing from the 
forward strand showing the rs1407428 SNP within HMNC1. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The M 
base called at position 144 (indicated with an arrow) represents the heterozygous 
rs17110878 SNP which occurs when both an A and a C base have equal fluorescence 





Figure 3.21 An electropherogram representing a segment of sequencing from the 
forward strand showing the rs1407428 SNP within HMNC1. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The A 
base called at position 148 (indicated with an arrow) represents the heterozygous 
rs17110878 SNP. 
 
  3.5.7 Detection of rs6425006 in HMNC1  
 
The heterozygous rs6425006 SNP was detected in seven out of 254 samples (Table 
3.7) and verified by cycle sequencing (Figure 3.22). The difference in minor allele 
frequency between the Caucasian AMD and Caucasian Control cohort respectively 
(Table 3.7), is not significant with a p value of 3.12 x 10-1. The difference in minor allele 
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frequency between the African AMD and African Control cohort respectively (Table 3.7), 
is not significant with a p value of 3.91 x 10-1. The wild type allele i.e. the absence of the 
rs6425006 SNP, in a sample was represented on the electropherogram by a red peak, 
indicative of a T allele (Figure 3.9). The presence of a heterozygous rs6425006 SNP in 
a sample was represented on the electropherogram by a red and black peak, indicative 
of a T and C allele, respectively (Figure 3.10). A homozygous rs6425006 SNP was 
represented by a single black peak, indicative of a C allele. 
   
 
 
Figure 3.22 An electropherogram representing a segment of sequencing from the 
forward strand showing the rs6425006 SNP within HMNC1. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The Y 
base called at position 131 (indicated with an arrow) represents the heterozygous 
rs6425006 SNP which occurs when both a T and a C base have equal fluorescence for 
that locus. 
  
  3.5.8 Detection of rs17110714 in ABCA4  
 
The heterozygous rs17110714 SNP was detected in nine out of 254 samples (Table 
3.7) and verified by cycle sequencing (Figure 3.23). The difference in minor allele 
frequency between the Caucasian AMD and Caucasian Control cohort respectively 
(Table 3.7), is not significant with a p value of 2.00 x 10-1. The difference in minor allele 
frequency between the African AMD and African Control cohort respectively (Table 3.7), 
is significant with a p value of 1.04 x 10-2. The wild type allele i.e. the absence of the 
rs17110714 SNP, in a sample was represented on the electropherogram by a red peak, 
indicative of a T allele (Figure 3.7). The presence of a heterozygous rs17110714 SNP in 
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a sample was represented on the electropherogram by a red and black peak, indicative 
of a T and C allele, respectively (Figure 3.8). A homozygous rs17110714 SNP was 




Figure 3.23: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs17110714 SNP within ABCA4. The actual sequence 
called is indicated above the peaks with each colour representing a different nucleotide. 
The Y base called at position 459 (indicated with an arrow) represents the heterozygous 
rs17110714 SNP which occurs when both a C and a T base have equal fluorescence 
for that locus.  
  
   
  3.5.9 Detection of rs6703052 SNP in ABCA4  
 
The heterozygous rs6703052 SNP was detected in 26 out of 254 samples and in the 
homozygous state twice (Table 3.7). Each separate genotype was verified by cycle 
sequencing (Figure 3.24) (Figure 3.25). The difference in minor allele frequency 
between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7), is 
not significant with a p value of 1.63 x 10-1. The difference in minor allele frequency 
between the African AMD and African Control cohort respectively (Table 3.7), is not 
significant with a p value of 5.01 x 10-1. The wild type allele i.e. the absence of the 
rs6703052 SNP, in a sample was represented on the electropherogram by a black 
peak, indicative of a C allele (Figure 3.7). The presence of a heterozygous rs6703052 
SNP in a sample was represented on the electropherogram by a black and green peak, 
indicative of a C and an A allele, respectively. A homozygous rs6703052 SNP was 






Figure 3.24: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs6703052 SNP within ABCA4. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The M 
base called at position 114 (indicated with an arrow) represents the heterozygous 
rs6703052 SNP which occurs when both an A and a C base have equal fluorescence 






Figure 3.25: An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs6703052 SNP within ABCA4. The actual sequence called 
is indicated above the peaks with each colour representing a different nucleotide. The A 
base called at position 114 (indicated with an arrow) represents the homozygous 
rs6703052 SNP.  
  
  3.5.10 Detection of rs17110878 in ABCA4 
 
The heterozygous rs17110878 SNP was detected in five out of 254 samples, and once 
in the homozygous state (Table 3.7). Each separate genotype was confirmed by cycle 
sequencing (Figure 3.26) (Figure 3.27). The difference in minor allele frequency 
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between the Caucasian AMD and Caucasian Control cohort respectively (Table 3.7), is 
not applicable since no minor alleles were genotyped in either cohort. The difference in 
minor allele frequency between the African AMD and African Control cohort respectively 
(Table 3.7), is not significant with a p value of 3.98 x 10-1. The wild type allele i.e. the 
absence of the rs17110878 SNP, in a sample was represented on the electropherogram 
by a green peak, indicative of an A allele (Figure 3.9). The presence of a heterozygous 
rs17110878 SNP in a sample was represented on the electropherogram by a green and 
blue peak, indicative of an A and a G allele, respectively (Figure 3.10). A homozygous 





Figure 3.26: An electropherogram representing a segment of sequencing from the 
forward strand showing the rs17110878 SNP within ABCA4. The actual sequence 
called is indicated above the peaks with each colour representing a different nucleotide. 
The R base called at position 136 (indicated with an arrow) represents the heterozygous 
rs17110878 SNP which occurs when both an A and a G base have equal fluorescence 









Figure 3.27: An electropherogram representing a segment of sequencing from the 
forward strand showing the rs17110878 SNP within ABCA4. The actual sequence 
called is indicated above the peaks with each colour representing a different nucleotide. 
The G base called at position 127 (indicated with an arrow) represents the homozygous 
rs17110878 SNP. 
 
  3.5.11 Detection of rs487906 in ABCA4  
 
The heterozygous rs487906 SNP was detected in 92 out of 254 samples and in the 
homozygous state once.  
 
The wild type allele i.e. the absence of the rs487906 SNP, in a sample was represented 
on the electropherogram by a blue peak, indicative of a G allele (Figure 3.13). The 
presence of a heterozygous rs487906 SNP in a sample was represented on the 
electropherogram by a blue and black peak, indicative of a G and C allele, respectively.  
A homozygous rs487906 SNP was represented by a single black peak, indicative of a C 
allele. 
 
However, of the six samples, covering all three possible genotypes, were sequenced in 
order to verify the genotyping results. Of the six samples, only one showed 
corresponding genotype results for cycle sequencing and SNaPshot reactions. 
SNaPshot genotyping for the remaining conflicting samples showed a heterozygous 
(C/G) genotype while cycle sequencing showed a homozygous Guanine genotype on 
the reverse strand (Figure 3.28). The forward strand was not used for sequence 
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analysis due to the intronic variant, rs375387843, situated upstream from rs487906 
SNP producing a deletion to frameshift the sequence and rendering it uninterpretable. 
   
 
 
Figure 3.28 An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs487906 SNP within ABCA4. The actual sequence called is 
indicated above the peaks with each colour representing a different nucleotide. The G 
base called at position 257 (indicated with an arrow) represents the homozygous 
rs487906 SNP. 
 
Ideally, an internal primer from the forward strand could be designed to resolve the 
incongruous genotype results but a SNP situated 11 bp upstream from the rs487906 
SNP would impede hybridization of the internal primer to the template. Possible reasons 
for the genotype discrepancy include internal primer design and poor DNA quality. 
Reasons for incorrect nucleotide extension with regard to internal primers include 
binding to other sequences in the amplified segment or hairpin and primer dimer 
formation enabling hybridization to an adjacent sequence. Degraded DNA could also 
explain the ambiguous results although it seems unlikely due to the same samples 
demonstrating accurate genotyping with the other SNPs in candidate AMD genes 
(Hansen et al. 2007). All SNaPshot genotype results were of satisfactory peak size with 
no or minimal background noise hence eliminating other causes of extraneous peaks 
such as incomplete removal of PCR primers and ddNTPs. Due to the genotype 
discrepancy, the rs487906 SNP genotype results were not incorporated into the final 




Further analysis of the sequencing results showed that four of the six samples 
contained two intronic variants 12 bp from the forward external primer. The first variant, 
rs375387843, caused a C/- allele feature truncation while the second variant, 




Figure 3.29 An electropherogram representing a segment of sequencing from the 
reverse strand showing the rs375387843 and rs71588510 SNPs within ABCA4. The 
actual sequence called is indicated above the peaks with each colour representing a 
different nucleotide. The Y and R base called at position 36 and 37 respectively 
(indicated with an arrow) represents the heterozygous CG/TA allele substitution. The 
heterozygous rs375387843 SNP at position 35 represents the heterozygous -/G allele 
substitution which is identified by multiple heterozygous peaks followed by normal 
sequence as one allele is shifted by the deletion of a G nucleotide. 
 
Webcutter version 2.0 (Maarek et al 1997) (http://rna.lundberg.gu.se/cutter2) was used 
to determine the suitability of RFLP as a genotyping technique to potentially genotype 
the AMD cohort for the two intronic variants, rs375387843 and rs71588510. The 
combination of the two intronic variants altered two RE recognition sites but resulted in 










Chapter 4: Discussion 
 
In this study, macular degeneration, in its ‘juvenile’ and ‘elderly’ form, namely STGD and 
AMD, was investigated among the indigenous southern African population respectively. 
In the first part of the study, following a SNP-based phased haplotyping of a cohort of 
indigenous South African subjects, the entire coding region of ABCA4 was screened in 
a small STGD cohort in pursuance of novel mutations to elucidate the missing 
heritability within this group. In the second part of this study, candidate AMD genes, in 
whom there were significant SNP allelic frequency differences between Caucasian and 
indigenous southern Africans were investigated as potential protective factors within an 
ethnically diverse AMD cohort to explain the considerably lower prevalence of AMD 
among indigenous southern Africans. Sections 4.1 to 4.1.5 pertain to the discussion 
concerning the first part of the study, while sections 4.2 to 4.2.4.1 relate to the second 
part of this study.  
 
4.1 Novel ABCA4 mutations in indigenous Africans with STGD 
 
Vast numbers of mutations have been identified within ABCA4 since its recognition as 
the causative gene for STGD (Allikmets et al. 1997a). Commercial microarrays, like the 
ABCR400, were developed to screen populations for numerous mutations 
simultaneously (Jaakson et al. 2003). Microarray chip screening in the past proved 
successful within the South African Caucasian population by detecting the causative 
mutations in 58.4 % of subjects. Seven common founder mutations emerged in the 
Afrikaner sub-cohort from this screening, resulting in a new diagnostic SNaPshot assay, 
the ‘Quick 7’ (Roberts et al. 2012), which is currently offered by the National Health 
Laboratory Services (NHLS) in South Africa. Subsequent screening of SA indigenous 
African STGD patients with the ABCR 400 microarray was disappointing, as only 11% 
had their causative mutations (homozygous or compound heterozygous) identified. To 
ascertain whether novel mutations were present within the black southern African STGD 
patient group, PHASE (Stephens et al. 2001) analysis of 17 SNPs across ABCA4 
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(which was available through these samples having been screened using the ABCR400 
array) indicated three common haplotypes within the African STGD group. The aim of 
this study was to discover novel mutations within the African STGD cohort by 
exploratory sequencing of the entire coding region of ABCA4 in three STGD patients 
representing each of the three common haplotypes.  
 
Four previously-reported missense mutations were detected during sequencing of 
ABCA4 among the three African STGD patients. ABCA4 currently has 761 reported 
mutations of which 517 are missense/nonsense mutations as indicated in the Human 
Genetic Mutation Database (HGMD) (www.hgmd.org). Interestingly, the NCBI variation 
viewer (www.ncbi.nlm.nih.gov/variation/view/) asserts that only 18 of these 517 are 
definitely pathogenic. Determination of pathogenicity in the present study involved 
multiple processes ranging from database and literature reviews to analysis through 
prediction software, namely PON-P (Olatubosun et al 2015) (http://bioinf.uta.fi/PON-
P/index.shtml), PON-P2 (http://structure.bmc.lu.se/PON-P2/) (Lund University, 2013) 
and Human Splice Finder (Desmet et al 2009) (13 October, 2010) 
(http://www.umd.be/HSF/#). Deciding upon pathogenicity is a complex process and 
involves consideration of multiple factors.  
 
The R226L mutation in ABCA4, although not novel, was listed among the missense 
variants within the HGMD database. This mutation was originally reported in Russian 
and Moldovian Hereditary Nonpolyposis Colon Cancer (HNPCC) families (Maliaka et al. 
1996). Both PON-P (Olatubosun et al 2015) and PON-P2 (Niroula et al 2015) classified 
its pathogenicity as ‘unknown’ and this mutation has not previously been reported in SA. 
No minor allele frequency data for the African populations was reported for this variant 
in the 1000 Genomes (McVean et al 2012) database. R226L did not track with any of 
the haplotypes and was only detected in one test sample, namely RPS1230.1. In view 
of the above factors R226L was considered unlikely to be pathogenic within this 




The V643M mutation (Briggs et al. 2001) was the only mutation still classified as 
pathogenic after re-analysis with PON-P2 (Niroula et al 2015). The wild type allele 
frequency is 99 % in African populations, screened in the 1000 Genomes project 
(representing Yoruba, Luhya and Americans of African descent), and the mutant allele 
was identified only in patient RPM 1075.1 after screening the whole Haplotype cohort. 
The mutation is listed in HGMD and associated with the STGD phenotype. Although 
classified as pathogenic by PON-P2, V643M was deemed benign within an African 
American STGD cohort based on similar allele frequencies among cases and controls in 
a population of African American descent (Zernant et al. 2014). Of all four missense 
variants identified in this study, V643M is the most likely pathogenic mutation as 
supported by software prediction and it is the only mutation of the four predicted to be 
pathogenic by Stone, using a substitution matrix called Blosum62 (Stone 2003).  
 
The L1201R mutation was first described when sequencing 150 recessive STGD 
families of northern and central European descent (Lewis et al. 1999). The L1201R 
mutation is listed similarly to V643M in HGMD, but differs in that its predictive 
pathogenicity was altered after re-analysis with PON-P2 (Niroula et al 2015). Ten 
percent of the African populations (1000 Genomes) screened, display the L1201R 
mutant allele which is remarkably similar to the allele frequency of 12.5 % within our 
Haplotype cohort. L1201R also displayed a high minor allele frequency (7.5 %) within 
an African American control population of 300 and identified as a non-pathogenic 
variant within 10 unrelated African American STGD patients within the same study (Utz 
et al. 2013a). Similarly, L1201R was deemed benign due to a high allele frequency in 
the general African American population when screened for in a cohort of 44 African 
American STGD patients (Zernant et al. 2014). Taking into account this high frequency 
within the African population, and considering that five to 12 percent of the general 
population screened positive for at least one ABCA4 mutation (Jaakson et al. 2003; 
Rivera et al. 2000; Riveiro-Alvarez et al. 2009) makes it an unlikely pathogenic mutation 




This notion is supported by software prediction, but should be confirmed by performing 
family co-segregation analysis. Co-segregation analysis forms an essential part in 
pathogenicity confirmation, especially in cases where a frequent disease-associated 
allele also shows a higher than expected allele frequency within a control population. 
This was shown with the R2107H mutation in an African American STGD cohort 
(Zernant et al. 2014). Co-segregation analysis was not possible due to lack of DNA from 
additional family members of any of the three Bs at the time of this study. This should 
be regarded as a limitation to pathogenicity prediction in this study.  
 
The final missense variant, S2255I, was previously reported among a European cohort 
of cone-rod dystrophy patients and is listed under that same phenotype in HGMD 
(Maugeri et al. 2000). A ‘caution’ to its classification as a pathogenic STGD mutation is 
the observation that the wild-type and mutant alleles occur with equal frequency within 
the African populations (1000Genomes). This observation is supported by the fact that 
two of the three test samples contain this variation, in a heterozygous state.  
 
Therefore, after incorporating all of the above facts, viewed within the context of a 
limited STGD cohort, V643M is classified as the only pathogenic missense mutation 
detected among the three test samples within this study. Further conclusive deductions 
regarding the pathogenicity of the other three missense mutations could only be made if 
functional protein and segregation studies are performed. As missense variants 
constitute the largest proportion of all mutations in ABCA4, their pathogenic prediction is 
important, especially as we detected no obvious disease-causing mutations such as 
deletions, insertions or nonsense mutations within the exons.  
 
  4.1.1 Pathogenic predictor software accuracy 
 
With the change in predictive class of the L1201R mutation, questions arose regarding 
the accuracy of pathogenic predictor software. Missense predictor software differs from 
other predictor tools in that they focus on predicting protein structural changes. These 
changes include the structure, stability and folding of the altered protein product. One of 
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the obstacles hampering predictor accuracy is that all missense predictor tools use 
different training datasets and machine learning methods, leading to bias. PON-P 
(Olatubosun et al 2015) overcomes this by incorporating many predictors whether they 
are structural or sequence-based.  This observation is expected in view of evolutionary 
forces actively selecting against deleterious variants. Thusberg et al. (2011) compared 
all missense predictor tools against large mutation databases for outcomes such as 
accuracy, sensitivity and specificity with most predictor tools scoring in excess of 70 % 
in accuracy. Although missense predictor tools are becoming more reliable and 
accurate (Galehdari et al. 2013), they still lack the ability to account for the pathogenicity 
of mutations affecting cellular pathways such as transcriptional regulation, micro-
ribonucleic acid (mRNA) splicing and exon silencing.  
 
Determination of pathogenicity of the four missense variants identified in this study was 
mainly based on the outcome of PON-P2 prediction when all other factors were 
considered. In summary, only the V643M mutation was deemed to be disease-causing. 
More novel and known missense variants were expected especially considering the 
allelic heterogeneity of ABCA4 and that this particular (indigenous African) ethnic group 
has not been investigated previously. The fact that only three samples were sequenced 
could have contributed to the low number of missense variants identified. Nonetheless, 
the fact that missense mutations were detected in each sample is encouraging. 
   
  4.1.2 Missing heritability in the STGD cohort 
 
No mutational screening process is complete without Copy Number Variants (CNV) 
screening. CNVs are structural alterations in the human genome which include 
deletions, duplications, translocations and insertions of chromosomal regions ranging 
from one kilobase to several megabases in size. The PCR-based methods and 
sequencing used in this study are unable to detect CNV mutations, hence the need for 
further screening with techniques such as multiplex ligation-dependent probe 
amplification (MLPA). Bauwens et al. (2013) reported a single deletion among 48 
patients with incomplete molecular diagnosis using a combination of qualitative PCR 
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(qPCR) and massive parallel sequencing, while Yatsenko et al. (2003) detected 
deletions in two out of 308 STGD subjects. In a study of 44 STGD patients using aCGH, 
no large CNVs were found in the ABCA4 locus (Zernant et al. 2014). Although these 
studies indicate the rarity of CNVs as the causative mutation in most STGD cohorts, it 
must still be considered as a possible cause of STGD among our African cohort. 
Testing the whole Haplotype cohort for CNV mutations would be much more effective in 
comparison to screening just the three test samples, considering the rarity of CNVs in 
STGD in the literature to date.  
 
An additional possibility for the lack of definitive mutations identified is that the African 
STGD cohort may contain causative mutations in a gene or gene(s) other than ABCA4. 
Autosomal dominant Stargardt-like macular dystrophy, known also as STGD type 3, has 
similar clinical features to the other forms of STGD but segregates in an autosomal 
dominant fashion (Stone et al. 1994). The causative mutation was mapped to ELOVL4, 
which is involved in the synthesis of very long chain saturated and polyunsaturated fatty 
acids, and located on chromosome 6q14. The role of ELOVL4 was confirmed by 
subsequent studies in other families showing a dominant inheritance pattern for 
inherited macular degeneration (Griesinger et al. 2000; Zhang et al. 2001). STGD type 4 
also shows a similar phenotype to STGD type 1. Yang et al. (2008) showed the 
causative mutation to be a missense mutation in PROM1 after an autosomal dominant 
STGD phenotype was identified within a Caribbean family (Kniazeva et al. 1999).  
 
Boon et al. (2007) reported a causative mutation within the peripherin 2 (RDS) gene for 
one-fifth of his patients with assumed STGD, after screening of ABCA4. RDS produces 
a protein that is essential for outer segment disk morphogenesis and leads to a slower 
macular degeneration than STGD. These studies illustrate the complexity in studying 
inherited macular degeneration disorders – not only are there major overlapping 
phenotypic features, but also genotypic heterogeneity among seemingly similar 
phenotypes. Extensive clinical diagnostic workup is therefore essential, especially when 




Braun et al. (2013) showed that mutations can be detected within non-exomic and 
splicing regions by using RNA sequencing and functional analysis for individuals where 
only one mutant ABCA4 allele had been identified. Although it is possible that the 
missing mutant alleles for our cohort are within the intronic region of ABCA4, the lack of 
additional familial samples with which to perform segregation analysis, and the large 
number of possible pathogenic intronic variants as indicated by HSF, complicates the 
choice of variant for subsequent functional analysis. In view of these challenges, it was 
prudent to only sequence exons and splice regions across the cohort compared to deep 
intronic sequencing. Since it has been shown that intronic variants up to 1Mb from the 
exon can be disease causing, it remains possible but improbable that the intronic 
regions of ABCA4 harbour the missing mutant alleles for this cohort.   
 
All intronic and synonymous variants were analysed with HSF to assess pathogenicity, 
yielding a total of 22 out of a possible 35 variants that were predicted to have a 
significant effect. Only three of the 22 variants were situated within the acceptor splicing 
region, of 10 to 15 bp, 5´ of the exon. Surprisingly, intronic variants in this cohort 
showed significant alterations as deep as 122 bp from the exon. If taken at face value, 
these results would mean that test sample three has a total of 16 pathogenic intronic 
and synonymous changes. For ease of interpretation, any significant change within this 
study will be assumed to be possibly pathogenic and therefore deserving further 
consideration. This creates a challenging situation as how to differentiate between these 
16 possible pathogenic changes as it would be improbable for any allele to contain so 
many mutated variants. Logically, one would focus on variants occurring within the 
presumed splicing region, but again no family data is available to test whether these 
variants co-segregate. Another difficulty arises when attempting to rank pathogenic 
predicted variants according to the particular element disturbed within the spliceosome, 
whether it be branching points or ESEs. These factors are not adequately addressed by 
the designers of the HSF suite of programmes in order for one to confidently consider a 
variant as definitely pathogenic. This is understandable as ESE analyses are 
incorporated within HSF output data and these predictions are based upon different 




Although ‘ESEfinder’ estimates have been shown to successfully predict aberrant 
splicing, there are instances when known splicing effects fail to associate with a 
sequence change that causes a reduction of the prediction score (Anczukow et al. 
2008). When interpreting results regarding splicing aberrations it is critical for 
supplementary expression studies, especially of a quantitative nature, as not all 
aberrant splice products are produced in amounts substantial enough to influence 
protein function. Whenever further functional analysis or segregation studies are 
planned pertaining to a certain variant, it is important to use multiple predictor tools 
when finalizing a decision (Spurdle et al. 2008).   
 
Considering all the above mentioned factors it is judicious to use the HSF predictions as 
a guide towards choosing a variant for further screening within our cohort rather than as 
a pathogenic predictor tool with diagnostic implications. Deciding which variant to 
investigate further was based upon multiple factors including variant position, population 
frequency and previous associations with equal weight given to HSF predictions.   
 
In a resource-finite setting as with the current study, accurate haplotype inference is 
vital in disease mapping (Rieder et al. 1999). Ideally, all 32 African STGD patients with 
no mutations identified would have been sequenced for novel mutations in ABCA4. The 
high cost and labour intensity of sequencing made computational haplotype 
reconstruction with PHASE (Stephens et al. 2001) an applicable alternative in this 
setting. PHASE (Stephens et al. 2001) uses a Bayesian inference method to assign 
haplotypes within a cohort consisting of genotyped data with no phase information and 
the accuracy of this method has been previously investigated by comparing it to 
observed values from 15 SNPs in Growth Hormone 1 (GH1) promoter region in 154 
recruits (Adkins et al. 2004) .  Correct haplotypes were allocated to individuals nearly 
90% of the time and 87% when unambiguous individuals were excluded. Accuracy is 
reduced with increasing amount of heterozygous SNPs especially more than five, 
according to the same study. Therefore, although possible, it is unlikely that PHASE 
(Stephens et al. 2001) incorrectly identified the common haplotypes in this African 
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STGD cohort of 32 patients. Possibly, the failure to discover novel mutations in ABCA4 
could also be attributed to disease-causing mutations tracking along other haplotypes 
within the cohort not assigned to any of the three sequenced individuals.  
 
Additionally, the possibility of reduced penetrance for certain variants in the African 
population, i.e. the L1201R mutation could be considered as it occurs at an allele 
frequency of ten percent in African populations and 12.5 % within the Haplotype cohort 
in this study. Penetrance refers to the percentage of individuals with a certain genotype 
that displays the associated phenotype. Penetrance can range from complete to 
incomplete to even pseudo-incomplete if clinical signs have not yet appeared at the time 
of examination. Different mechanisms, as discussed below, influence the degree of 
penetrance within a certain ethnic or population groups (Cooper et al. 2013).  
  
  4.1.3 Screening of the Haplotype Cohort 
 
Variants were divided among the three common haplotypes, and for Haplotype four and 
12, more than half the variants were considered significant changes. Only three variants 
tracked with Haplotype 29. Selecting a single variant per haplotype to further screen 
among the cohort was not straightforward due to the same concerns that applied when 
analyzing the HSF predictions. Owing to the lack of obvious exonic mutations and over-
signifying the effects of the splicing and silent variants, it was concluded that no obvious 
variants correlated with the haplotypes, and thus the haplotype grouping of variants was 
abandoned. The three most likely pathogenic variants were then selected in order to 
determine their presence within the Haplotype cohort. The variants selected were 
L1201R and V643M, and the synonymous variant T1277T. The missense variants were 
clear choices, for reasons explained above, while the T1277T variant displayed 
significant changes in HSF, exhibited a low minor allele population frequency and was 
situated close to the donor splicing site. Ascertaining the frequency of these variants in 
even such a small cohort still provides insights into the possible pathogenicity of these 




The V643M mutation allele was not present within the Haplotype cohort which was 
expected considering its one percent population frequency within African control 
populations extracted from the 1000 Genomes (McVean et al 2012) resource. With such 
a small cohort, no meaningful deductions can be made concerning this mutation within 
the African STGD population in SA. 
 
The L1201R variant allele frequency in African control and Haplotype cohort groups was 
10 and 12.5 % respectively, as mentioned above. This confirms the conjecture that this 
variant seems to be a normal, benign polymorphism within this population. The same 
assumption made for the L1201R variant applies to the T1277T variant as the genotype 
frequencies for African and haplotype groups were three and six percent, respectively. 
These results consolidate our beliefs regarding each variant’s non-pathogenic status. 
 
Ultimately no sample in the haplotype cohort, or the test cohort, could be characterised 
with two bi-allelic pathogenic ABCA4 mutations, hinting at other genes underlying the 
retinal dystrophies manifesting as STGD in this population group. Whole exome 
sequencing is recommended in order to elucidate the genetic basis of disease.       
 
  4.1.4 STGD study limitations 
 
The three test samples were diagnosed using only fundal assessment and 30° fundus 
photograph, whereas had they received additional fundus autofluorescence (AF) 
imaging and optical coherence tomography (OCT) they might have been diagnosed 
differently with a disorder within the STGD differential such as Fundus Albipunctatus, 
Retinitis Punctate Albescens or Best Disease. This lack of extensive clinical data results 
in improper gene targeting, as for example in the case of Best disease, one would have 
to screen the Vitelliform Macular Dystrophy 2 gene for mutations.  
 
The lack of familial data for all three test samples again prevents confirmation of the 
autosomal recessive pattern expected in these STGD patients, adding to the diagnostic 
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dilemma and supports the recommendation to screen other genes in order to complete 
the molecular diagnosis for this cohort. 
 
A noted limitation with the predictor tool, ESEfinder, is that it recognizes disruption or 
creation of potential ESE-binding sites but gives no information regarding which sites 
are most likely to be used under normal physiological or pathophysiological conditions. 
These sites are also poorly defined and influenced by multiple factors such as strength 
and distance from the splice site (Fairbrother et al. 2004). 
 
  4.1.5 Future work 
 
Notwithstanding the infrequency of positive CNV mutational screening in STGD cohorts, 
it is still an integral component of comprehensive screening within undiagnosed cohorts 
i.e. this current study. Testing the whole Haplotype cohort for CNV mutations would be 
much more effective in comparison to screening just the three test samples. CNV 
analysis forms part of the future plans for further elucidating the causal mutations within 
this cohort. In future it would be recommended to either do exome or full genome 
sequencing on all 14 haplotype samples. Whole exome sequencing would cover all 
known MD candidate genes, and could also allow the identification of novel candidate 
genes. However, a large number of variants is expected to occur in each sample, 
therefore DNA from multiple affected and unaffected family members is required in 
order to analyse segregation of variants with the disease. Importantly, however, 
emphasis also does need to be placed on the desirability of detailed ophthalmological 
phenotyping of subjects and their relatives who end up being part of the study. 
 
4.2 Protective genetic factors in indigenous Africans with AMD 
 
Past epidemiological studies have categorically shown elderly Caucasian populations to 
be more susceptible to AMD than their African counterparts (Klein et al. 2006; Bressler 
et al. 2008). This difference persists even when both groups are derived from the same 
geographical region, further suggesting that genetic factors are responsible (Friedman 
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et al. 1999). AMD is a complex disease resulting from interplay of numerous modifiable 
and non-modifiable risk factors. To date, none of these risk factors have been able to 
fully account for the discrepancy in prevalence of AMD between these two ethnic 
groups (Klein et al. 2008).  
 
As a complex disease, AMD is unique in that approximately half of its genetic heritability 
is accounted for by only a few susceptibility loci (Swaroop et al. 2007). Some of these 
susceptibility loci fail to associate with AMD in replicate studies within other ethnic 
groups, suggesting that modifier or protective genetic factors play a role within these 
groups. Mostly, protective factors track exclusively within an ethnic group, like the ApoE 
ɛ4 allele and SNPs in the complement genes, CFB and CC2, within Caucasians (Baird 
et al. 2004; Spencer et al. 2007). Occasionally, an unlikely factor confers protection 
across multiple ethnic groups, such as the CFH haplotype, linking to a 
delCFHR1/CFHR3 mutation (Hagemann et al. 2006). As the group exhibiting the lowest 
prevalence of AMD among all ethnic groups, Africans present the ideal cohort in which 
to identify candidate protective genetic factors. This study aimed to establish whether 
protective genetic factors exist within the African population in SA in selected AMD 
candidate genes.  
 
The AMD cohort consisted of patients of Caucasian, Mixed Ancestry and African 
ethnicities. A large proportion of this cohort was obtained from the Retinal Registry in 
the Division of Human Genetics at UCT, previously recruited for the RDD project. The 
rest of the cohort was recruited in collaboration with Ophthalmologists in the 
Department of Ophthalmology at Groote Schuur Hospital in Cape Town. A single 
African AMD patient was recruited during the year and a half long recruitment drive. 
This serves to illustrate not only the anecdotal low prevalence of AMD in SA Africans, 
but also the difficulties with AMD research within this ethnic group in SA.    
 




Only samples fully genotyped for all ten SNPs in candidate AMD genes were used for 
further analysis. Singleplex PCR was used to genotype SNPs that were not amplifying 
within their multiplex groups. Generally, the longer amplicons (>350 bp) within each 
multiplex group were resistant to amplification even after repeated attempts. This was 
most likely attributed to DNA degradation that inevitably occurred in samples stored for 
extended periods of time. Or it could be simply due to the physicochemical principles 
which favour the preferential and complete amplification of the shorter amplicons. Either 
way, because of the lack of amplification of the larger amplicons, 18 % of samples were 
not included in the final data analysis. The resolution of one SNP, rs487906, within 
multiplex group three proved problematic when attempting amplification, even after 
satisfactory optimisation. Subsequently, it was amplified using singleplex PCR leaving 
multiplex group three with only two SNPs. 
 
After screening the entire AMD cohort, SNP genotypes were confirmed with direct cycle 
sequencing. Not less than five percent of samples for each SNP were cycle sequenced 
in order to accurately validate genotypes. All displayed genotypes for each SNP were 
included within the samples selected for sequencing. Of all the SNPs in candidate AMD 
genes screened, only one showed conflicting cycle sequencing and SNaPshot results, 
namely rs487906, the same SNP removed from multiplex group three.  Owing to this 
discrepancy, SNP rs487906 results were not included in the final data analysis. 
Technical reasons for this include either incorrect primer design or DNA quality 
variation. For the remaining nine SNPs, data analysis was performed using the online 
software program SHEsis (Yong 2005) to determine whether there was a significant 
difference in the MAF of the AMD cohort for each SNP.  
 
Another technical factor to consider is the possibility of incorrect SNP genotyping, 
although SNaPshot provided clear results. This conflict in genotype evaluation has 
previously been assessed with similar techniques and equipment as was used in this 
study (Hansen et al. 2007). Using large sample sizes they confirmed a genotype 
discrepancy of between six and 15 % after cycle sequencing using the ABI Prism 
3130xl Genetic Analyzer (Applied Biosystems). Again due to financial constraints, 
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confirmation of SNaPshot genotypes involved sequencing of roughly five to ten percent 
of the cohort of each SNP assuring inclusion of each possible genotype. Due to the 
small sample size of the African cohort, incorrectly assessed genotypes could alter the 
p value sufficiently to alter significance. However, the concordance of the sequencing 
and genotyping results in this particular study show this was not likely to be the case, 
other than for SNP rs487906 which was discarded from further data analysis.           
 
  4.2.2 Proposed role of protective AMD variants 
 
The first step in data analysis was to compare the MAF of the selected SNPs, between 
the Caucasian control and the AMD Caucasian cohort, respectively. By demonstrating 
that no significant differences exist between these MAFs, it consolidated the premise 
that these SNPs could confer protection within the African population only, by virtue of 
their overrepresentation in that particular group. The MAFs of all nine SNPs showed no 
significant difference between Caucasian control and AMD cohorts. Both the Caucasian 
control and AMD cohorts had similar sample numbers, 100 and 98, respectively. The 
second step was then to compare the MAF between the African control and the African 
AMD cohorts respectively. Contrary to the Caucasian cohorts, the African control cohort 
comprised 70 samples while the African AMD cohort contained only nine samples. Eight 
of the nine SNPs showed a decreased trend in the MAF in the AMD cohort, but only two 
of these, rs9621622 and rs17110714, showed a statistically significant decrease in 
cases, when using the threshold p value of 0.05. Another SNP, rs1555494, located in 
the intronic region in HMCN1 also showed a decreased MAF in the AMD cohort with a p 
value of 0.068. SNP rs9621622 is situated within the intronic region of TIMP3 while 
rs17110714 is located 838 bp 3′ downstream of ABCA4.  
 
TIMP3 (together with a range of other TIMPs, and the Matrix Metalloproteinases or 
MMPs) is involved in regulation of the ECM and plays a pivotal role in drusen buildup, 
which in turn accelerates the onset of AMD. Earlier studies have uncovered 
susceptibility SNPs within (European) Caucasian and Indian populations (Ristau et al. 
2014; Kaur et al. 2010), but neither risk nor protective alleles have been discovered 
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within African populations. ABCA4, the causative gene for STGD type 1, has previously 
been postulated to associate with AMD but contradictory results from studies within 
other population groups have caused uncertainty among the research community 
(Allikmets et al. 1997b; Rivera et al. 2000). This study provides the first suggestion of a 




    4.2.2.1 Protective SNP rs9621622 and TIMP3 
 
The ECM presents a system of endogenously produced macromolecules, consisting 
mainly of adhesive and structural fibrous proteins interlinked with polysaccharide 
glycosaminoglycans. Apart from functioning as the adhesive between cells, the ECM 
controls multiple cellular functions, including migration, adhesion and proliferation (Teti 
et al. 1992). Integral to the homeostasis of the ECM is the continual balance between 
synthesis and degradation process. This balance is maintained via the interplay 
between MMPs and TIMPs.  
 
The zinc-dependent MMPs ability to catabolize structural proteins like elastin and 
collagen enables essential physiological functions such as tissue remodeling, repair and 
angiogenesis. To prevent uncontrolled degradation of the ECM, TIMPs regulate MMP 
activity when inflammatory and tissue remodeling processes are activated. In contrast to 
other TIMPs, TIMP3 binds to the ECM once released from the RPE and is present in 
BM under physiological conditions (Teti et al. 1992). Within BM, TIMP3 both regulates 
the rate of ECM turnover and restricts CN, once initiated.  
 
One of the early factors in AMD pathogenesis is thickening of BM which occurs as part 
of normal aging. Overexpression of TIMP3 resulting in excessive deposits within soft 
drusen contributes to the age-related BM thickening (Kamei et al. 1999). Excessive 
TIMP3 results in retardation of BM renewal due to its MMP inhibitive properties. The 
increase in BM thickening in turn leads to a decrease in permeability and ultimately in 
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RPE atrophy. Subsequent to RPE atrophy, TIMP3 expression is vastly reduced 
resulting in unopposed neovascularisation from MMPs (Kamei et al. 1999).  
 
Considering the role of TIMP3 within the pathogenesis of AMD it is possible that a 
protective SNP, such as rs9621622, could alter TIMP3 expression within the SA African 
population. Decreased expression might lead to less accumulation within BM while 
maintaining sufficient levels to regulate MMP activity. Alternatively, the intronic SNP 
rs9621622 could be associated with an undiscovered protein-altering variation that 
results in reduced translation or alternate isoforms of the TIMP3 protein. Kobayashi et 
al. (2013) have previously illustrated this through a genome-wide association study in a 
Japanese population. This study showed that the C allele of an intronic SNP, rs130293, 
in TIMP3 associated with resistance to high-altitude pulmonary edema and suggested a 
functionally reduced TIMP3 as the responsible factor. Bearing in mind the complexity of 
ECM turnover within the pathogenesis of AMD, it is likely that SNP rs9621622 is merely 
one of many role players contributing to the protective effect detected in Africans, or it 
itself may be in linkage disequilibrium with a functionally relevant genomic variant.  
 
    4.2.2.2 Protective SNP rs17110714 and ABCA4 
 
Photon capture within the retina is possible due to the continuous renewal and 
circulation of Vitamin A derivatives between the RPE and POS. ABCA4, an ABC 
importer, is located on the outer margins of photoreceptors and functions to flip NR-PE 
and PE from the POS lumen to the cytoplasmic side. This process prevents the toxic 
accumulation of the pyridinium compound, A2E, in the RPE as lipofuscin. The initial 
facet in this process is the ATP binding to the internal nucleotide binding domains which 
leads to modification of the transmembrane-domain ligand binding site enabling binding 
of NR-PE and ATR with high affinity. Hydrolysis of ATP results in a conformation 
change of the channel and subsequent movement of the substrates intracellularly 




Retinal lipofuscin deposits are ubiquitous across all ethnicities and starts accumulating 
within the first two decades of life indicating that clearance mechanisms are sub-
optimal. A2E forms part of lipofuscin deposits and therefore optimal ABCA4 function is 
crucial to limit accelerated lipofuscin deposition. Clinical symptoms only arise after a 
certain threshold of deposition is reached. It is therefore sensible to suggest that certain 
ABCA4 genetic factors provide protection against AMD through minor enhancements in 
the process of substrate removal from POS. These could include: an increased rate of 
ATP-ase activity, increased binding affinity to substrates, increased transfer rate at 
lower substrate concentrations and reduction in phospholipid asymmetry within 
photoreceptor membranes (Quazi et al. 2012).  
 
Therefore, these two SNPs are hypothesised to be candidate protective factors for AMD 
within the SA African population. The locations of these two SNPs serve to provide 
focus for future research to further assist in elucidating the full genetic contribution of 
AMD in the African population in SA, and possibly the rest of Africa. 
 
  4.2.3 AMD study limitations 
 
The discovery of these two protective SNPs, albeit statistically significant, should be 
critically viewed when considering the limitations within this study. A cohort sample size 
of only nine AMD African patients is the most obvious factor impacting the conclusions 
made within this study. This limitation was expected, as the African AMD patients are 
infrequent within Ophthalmology clinics in SA. This is further hampered by the majority 
of African patients in SA being situated within rural areas where a lack of infrastructure 
prevents healthcare access. A further confounding factor is that the life expectancy in 
2014 in SA was 61.2 years which is below the recruitment age for AMD patients 
(http://beta2.statssa.gov.za/publications/P0302/P03022014.pdf).  
 
Another shortcoming owing to the sub-optimal recruitment, within selected cohorts is the 
lack of distinction between AMD subtypes, namely dry and wet AMD. Epidemiological 
studies have shown that the same ethnic group can display dissimilar prevalence rates 
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of dry AMD depending on the geographical area studied (Rosenberg et al. 1987a; 
Rosenberg et al. 1987b). Genome wide linkage studies that stratified families between 
AMD phenotypes (dry and wet AMD) have shown different genetic loci associated with 
each phenotype (Majewski et al. 2003; Abecasis et al. 2004). This current study is 
therefore unable to distinguish whether these two protective SNPs play a role within dry 
or wet AMD which is a significant limitation for future research based on this work, as 
treatment currently only exists for wet AMD.  
 
Only one patient of the African AMD cohort was recruited specifically for this study in 
collaboration with Ophthalmologists at the Ophthalmology Department of Grootte 
Schuur Hospital in Cape Town. This patient’s diagnosis was optimally confirmed and 
investigated as described in section 2.1.3, which is not the case with the other eight 
patients within the African AMD cohort. Interestingly, this patient also showed the least 
heterozygosity for the nine SNPs in candidate AMD genes among the nine African AMD 
patients with only two of these nine SNPs occurring in the heterozygous state. Some of 
these African AMD patients, accessed from within the UCT Retinal Registry, had sub-
optimal diagnostic investigations, sometimes consisting only of fundoscopy by a trained 
Ophthalmologist, but without retinal photographs. This same limitation applies to the 
Caucasian and Mixed Ancestry AMD cohorts although a larger proportion of these 
patients were recruited optimally when compared to the African AMD cohort as 
described above.  
 
Ideally, AMD case and control cohorts of each ethnic-group ought to be derived from 
the same geographic region to decrease the likelihood of genetic confounders. The 
African AMD and control cohort were both taken from equivalent SA African groups, the 
only difference being the proportions of each ethnolinguistic sub-group within each 
cohort. Conversely, data for the Caucasian control group was derived from the 1000 
Genomes CEU population. This group is of Northern and Western European descent 
while the AMD Caucasian cohort was recruited mostly out of the Western Cape of SA. 
However, upon deeper examination of the allele frequencies between ‘cases’ and 
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‘controls’ as shown in Table 3.7, one can gauge that this choice of the 1000 Genome 
Caucasian data as controls was legitimate.   
 
Another possible limitation is that SNP selection was restricted by those represented by 
the Human SNP 6.0 microarray from Affymetrix (Santa Clara, CA, USA, 1992), which 
was used to genotype the African control cohort. This chip genotyped a relatively large 
number of SNPs genome-wide (i.e. 906 600), the data available for the Caucasian 
controls was effectively that from whole genome sequencing. Therefore, the choice of 
SNPs displaying an increased frequency was limited to those available within the SNP 
6.0 chip.  In mitigation, however, almost always, even with the availability of whole 
genome sequencing data, exploratory studies such as the one presented here rely on 
subsets of data that are comparable and workable.  The 906 000 SNPs representing 
indigenous southern African populations, may simply be seen as ‘tagging reagents’ 
being adequate to interrogate regions of the genome for allelic differences – and these 
regions are effectively the whole genome. 
  
  4.2.4 Future work 
 
Funding and time constraints allowed only ten SNPs to be genotyped in this pilot AMD 
study, but ideally all variants (69) that displayed an increased frequency within African 
control group compared to Caucasian controls should be investigated. Future work 
would include replicating this study using larger, more clinically defined cohorts to 
improve statistical power and assess whether these findings replicate. It could also 
provide clarification on SNPs showing marginal significance such as rs1555494 within 
HMCN1. Candidate genes have historically been selected based on their association 
with increased susceptibility to a disease which is also the case with AMD. Candidate 
protective factors or modifiers could possibly exist outside of these candidate genes and 
to find these factors would require use of genome-wide studies and large case cohorts. 
Future work could include using genome sequencing data when performing these 
population-based comparative studies to find protective factors located within the 
genome outside of candidate genes. This would be incomplete without fully sequenced 
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Caucasian and African control populations from within the same geographical area as 
case cohorts to provide a more accurate comparison.    
 
Considering the possible effect of SNP rs9621622 on TIMP3 expression, it would be 
prudent to quantify and compare BM TIMP3 levels among Caucasian and African 
cohorts with immuno-histological staining techniques. Illustrating a significant lower 
TIMP3 concentration in BM of African controls compared to Caucasian controls and 
AMD cases would provide tentative support for the hypothesis that SNP rs9621622 
associates with a protective marker within TIMP3.   
 
    4.2.4.1 Implications within Mixed Ancestry population  
 
Within the Mixed Ancestry (MA) AMD cohort (18), a trend of increasing heterozygosity 
was noted when compared to the Caucasian AMD cohort (section 3.5). The MA 
population forms the major ethnic group (49.6 %) in the Western Cape of SA, from 
where the AMD cohort was recruited for this study 
(http://beta2.statssa.gov.za/publications/P0302/P03022014.pdf). The different 
(increased) MAF within the MA cohort is to be expected as this group represents 
admixture from four different populations namely: Xhosa, Europeans, South Asians and 
Indonesians (Patterson et al. 2010). In addition to elucidating the various ethnic 
contributions to the MA group in the Western Cape, Patterson et al. (2010) showed the 
viability of using the MA population for admixture gene mapping. Compared to 
association and linkage studies, admixture mapping has greater statistical power and 
requires fewer genetic markers to detect loci that contribute to ethnic discrepancy in 
complex disease susceptibility (Patterson et al. 2010).  Due to the MA group’s 
complexity, admixture mapping techniques could present technical difficulties but further 
investigation within this population is needed to increase the understanding of the 






In conclusion, a number of variants were identified in screening of ABCA4 in individuals 
exhibiting three unique haplotypes around this gene – however only one of the variants 
was validated as disease causing through various pathogenicity prediction tools. Apart 
from the possibility of phenotypic heterogeneity, it is possible that the disease causing 
mutation may lie in one of the other two known STGD-genes (ELOVL4 or PROM1), or it 
may hint at the existence of a novel gene. Furthermore, this pilot study discovered two 
possibly protective SNPs for AMD within the SA indigenous African population. It is 
tempting to speculate that understanding the genetic factors that protect the SA African 
population from AMD is the initial step in the process of developing locally relevant 
therapies for individuals affected and predisposed to AMD, thereby enhancing the 
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Appendix 1:Reagents  
 
10X TBE buffer (stock) 
 
216g (0.89M) Tris (B&M Scientific cc, Cape Town, SA) 
110g (0.89M) Boric Acid (ICN Biomedical Inc., USA) 
14.8g(0.04M) EDTA (BDH Electron® Laboratory Supplies, UK) 
Made up to 2L with H2O 
 
1X TBE buffer (working stock) 
 
A 10X dilution of the TBE buffer (stock) was made up using H2O 
 
2% agarose gel (50ml) 
 
1g agarose (Lonza,Seakem® LE, Rockland, USA) 
50ml 1 X TBE buffer 




0.125g (0.25%) Bromophenol Blue (Merck KgaA, Germany) 




Made up to 50ml with SABAX dH2O (Adcock Ingram, Johannesburg, SA) 
 
Appendix 2: Molecular weight marker 
 
GeneRuler™ 100bp DNA Ladder Plus (Fermentas Life Sciences, Hanover, USA): 25µl 
molecular weight marker stock solution 
 
 
Appendix 3: Genescan™ size standard 
 
Genescan™ -120LIZ® (Applied Biosystems, Warrington, UK) 





Appendix 4: AMD candidate genes 
The list of 24 genes associated with AMD that was extracted from Genetics Home 
Reference (http://ghr.nlm.nih.gov/condition/age-related-macular-





























Appendix 5: External primers for ABCA4 
 
Exon F-PrimerSequence R-PrimerSequence 
1 5' GACCAATCTGGTCTTCGTG 3' 5' GTTTATTTGCTCCACACCTC 3' 
2 5' TAGCACCACTGAACTTTCTC 3' 5' AAGGCCCAGACCAAAGTCTC 3' 
3 5' CCTGCTTGGTCTCCATGAC 3' 5' ACGTGAAGGGGTGTGCAAC 3' 
4 5' AGCATGAGATATTATTACTG 3' 5' AGTCTCTCCATAGGTGAGG 3' 
5 5' GACCCATTTCCCCTTCAAC 3' 5' AGGCTGGGTGCTTCCCTC 3' 
6 5' GGTGTCTTTCCTACCACAG 3' 5' AGGAATCACCTTGCAATTGG 3' 
7 5' GTGCCTATGTGTGTATATACC 3' 5' ATAAGTGGGGTAAATGGTGG 3' 
8 5' CGCAGCTGGATTAAGGATTG 3' 5' CCCAGGTTTGGTTTCACCTAG 3' 
9 5' AAGCAATGGGGAGTTTCTG 3' 5' GAGATGTGCTACCAGGAAG 3' 
10 5' GATAGGGGCAGAAAAGACAC 3' 5' CAAGTGGAACTTTGTTGCCC 3' 
11 5' CTAAGCAGAGCAGTGACTG 3' 5' ACTTGACTTGCTAAGGGAG 3' 
12 5' AGCCCTTATCCTGTGACTTTC 3' 5' TCCAGTCTCAATCCCTTTCTC 3' 
13 5' AGCTATCCAAGCCCGTTCC 3' 5' CCATTAGCGTGTCATGGAG 3' 
14 5' CCTGTTTTCCTTTCCCTCCATC 3' 5' TCTTTGAGTGTCTCCCACGTTG 3' 
15 5' AGGCTGGTGGGAGAGAGC 3' 5' AGTGGACCCCCTCAGAGG 3' 
16 5' CTGTTGCATTGGATAAAAGGC 3' 5' GATGAATGGAGAGGGCTGG 3' 
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17 5' CTGCGGTAAGGTAGGATAGGG 3' 5' CACACCGTTTACATAGAGGGC 3' 
18 5' CTCTCCCCTCCTTTCCTG 3' 5' GTCAGTTTCCGTAGGCTTC 3' 
19 5' TGGGGCCATGTAATTAGGC 3' 5' TGGGAAAGAGTAGACAGCCG 3' 
20 5' ACTGAACCTGGTGTGGGG 3' 5' TATCTCTGCCTGTGCCCAG 3' 
21 5' GTAAGATCAGCTGCTGGAAG 3' 5' GAAGCTCTCCTGCTCCAAGC 3' 
22 5' CTCTTCCTCACCCTCCACAGC 3' 5' GCTAGGGCTGCAGTGAGA 3' 
23 5' AGACACTGTGTGTGGCAATG 3' 5' CCTGTGTGAGTAGCCATGTC 3' 
24 5' ATGTGTTGACTACACTTGGCAG 3' 5' GCATCACAACAGGACACACC 3' 
25 5' GGTAACCTCACAGTCTTCC 3' 5' GGGAACGATGGCTTTTTGC 3' 
26 
5' CTTGTGGTTACTGTGTGCTTACG 
3' 5' TCGAACTCAGGTGGTCCATC 3' 
27 5' GAGATCCAGACCTTATAGGC 3'' 5' ACTGAGCTCAGCTAAACACCG 3' 
28 5' CCACCAGGGGCTGATTAG 3' 5' CCCAAACCCACAGAGGAG 3' 
29 5' GTTGCATGATGTTGGCACG 3' 5' CTTAGGACAGGGGCGCG 3' 








32 5' GAAAGTTAACGGCACTGC 3' 5' CATGGCTGTGAGGTGTGC 3' 
33 5' GCACAGACCAGATGCAGAAG 3' 5' GAGGCCTCTCTAGTGATAGG 3' 
34 5' GCTTAACTACCATGAATGAG 3' 5' ATTCCTTGCTAGATTTCAGC 3' 
35 5' GCAGCGTCTCAGATGTCCTC 3' 5' AAGAGTGGAGAAGGTGACAAG 3' 
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36 5' GTATCTTCTCCTCCTTCTGC 3' 5' ACACACAAGCTCCACCTTG 3' 
37 5' TTGCAGAGCTGGCAGCAG 3' 5' CCACCAGGCTTCTCTCTTCAG 3' 
38 5' GGAATGGAATGTGGAACTCC 3' 5' ACACATACTCTACTATCCTAC 3' 
39 5' GCCCCACCCGCTGAAGAG 3' 5' TCCCAGCTTTGGACCCAG 3' 
40 5' AGCTGGGGCGGCTGAAG 3' 5' TGCCCTGAGCTGCCCAC 3' 
41 5' GGACACTGTACAGCCAGC 3' 5' GACGAGTTATAACACAGGG 3' 
42 5' GTCACAGTTCTCAGTCCGG 3' 5' GGAGGAGAGGCAGGCAC 3' 
43 5' CTTACCCTGGGGCCTGAC 3' 5' CTCAGAGCCACCCTACTATAG 3' 
44 5' GAAGCTTCTCCAGCCCTAGC 3' 5' TGCACTCTCATGAAACAGGC 3' 
45 5' GTTTGGGGTGTTTGCTTGTC 3' 5' ACCTATTTCCCCAACCCAAGAG 3' 
46 5' GAAGCAGTAATCAGAAGGGC 3' 5' GCCTCACATTCTTCCATGCTG 3' 
47 5' CACATCCCACAGGCAAGAG 3' 5' AGGTGGATCCACAGAAGGC 3' 
48 5' ATTACCTTAGGCCCAACCAC 3' 5' ACACTGGGTGTTCTGGACC 3' 
49 5' GTGTAGGGCGCTGTTTTCCTG 3' 5' GCTCTGAGCCAAGGAACTG 3' 
50 5' AGTGCCTCAGCTGAGTGC 3' 5' CCAGCTGCCCAGAGTTCC 3' 
 
Appendix 6: Recruitment forms 












Appendix 7: 17 ABCA4 SNPs for Haplotype Analysis using PHASE 
 
SNP Ensembl Location Distance 
(bp) 
 
Exon 6 - 635G>A, R212H 
rs6657239 
94564483 -  
Exon 10 - 1268A>G, H423R  
rs3112831                  
94544234 20 249  
Exon 10 - 1269C>T, H423H 
rs4147831 
94544233 1  
IVS10+5delG, rs4147887   94544135 98  
Exon 19 - 2828G>A, R943Q  
rs1801581 
94512565 31 570  
Exon 28 - 4203C>A/T, P1401P 
rs1801666 
94496602 15 963  
IVS33+48C>T, (c.4773+48 C>T) 
rs472908  
94487354 9 248  
Exon 40 - 5603A>T, N1868I 
rs1801466 
94476467 108 87  
Exon 40 - 5682G>C, L1894L 
rs1801574  
94476388 79  
Exon 41 - 5814A>G, L1938L 
rs4147857 
94474328 2 060  
Exon 42 - 5843C>T, P1948L 
rs56142141  
94473846 482  
Exon 42 - 5844A>G, P1948P 
rs2275029 
94473845 1  
Exon 44 - 6069C>T, I2023I 
rs1762114   
94471075 2 770  
Exon 45 - 6249C>T, I2083I 
rs1801359 
94467447 3 628  
Exon 46 - 6285T>C, D2095D 
rs1801555 
94466659 788  
IVS48+21C>T, rs1800699  94463396 3 263  
Exon 49 - 6764G>T, S2255I 
rs6666652 
94461717 1 679  
 
